Published in final edited form as:

Acta Neuropathol. 2015 February ; 129(2): 183–206. doi:10.1007/s00401-015-1386-3.

Amyloid β oligomers in Alzheimer's disease pathogenesis, treatment, and diagnosis

Kirsten L. Viola

Neurobiology, Northwestern University, Evanston, IL 60208, USA

William L. Klein

Neurobiology, Northwestern University, Evanston, IL 60208, USA

Cognitive Neurology and Alzheimer's Disease Center, Northwestern University, Chicago, IL 60611, USA

Chemistry of Life Processes Institute, Northwestern University, Evanston, IL 60208, USA

Abstract

Protein aggregation is common to dozens of diseases including prionoses, diabetes, Parkinson's and Alzheimer's. Over the past 15 years, there has been a paradigm shift in understanding the structural basis for these proteinopathies. Precedent for this shift has come from investigation of soluble A β oligomers (A β Os), toxins now widely regarded as instigating neuron damage leading to Alzheimer's dementia. Toxic A β Os accumulate in AD brain and constitute long-lived alternatives to the disease-defining A β fibrils deposited in amyloid plaques. Key experiments using fibril-free A β O solutions demonstrated that while A β is essential for memory loss, the fibrillar A β in amyloid deposits is not the agent. The AD-like cellular pathologies induced by A β Os suggest their impact provides a unifying mechanism for AD pathogenesis, explaining why early stage disease is specific for memory and accounting for major facets of AD neuropathology. Alternative ideas for triggering mechanisms are being actively investigated. Some research favors insertion of A β Os into membrane, while other evidence supports ligand-like accumulation at particular synapses. Over a dozen candidate toxin receptors have been proposed. A β O binding triggers a redistribution of critical synaptic proteins and induces hyperactivity in metabotropic and ionotropic glutamate receptors. This leads to Ca²⁺ overload and instigates major facets of AD neuropathology, including tau hyperphosphorylation, insulin resistance, oxidative stress, and synapse loss. Because different species of A β Os have been identified, a remaining question is which oligomer is the major pathogenic culprit. The possibility has been raised that more than one species plays a role. Despite some key unknowns, the clinical relevance of A β Os has been established, and new studies are beginning to point to co-morbidities such as diabetes and hypercholesterolemia as etiological factors. Because pathogenic A β Os appear early in the disease, they offer appealing targets for therapeutics and diagnostics. Promising therapeutic strategies include use of CNS insulin signaling enhancers to protect against the presence of toxins and elimination of the toxins through use of

highly specific A β O antibodies. An AD-dependent accumulation of A β O in CSF suggests their potential use as biomarkers and new A β O probes are opening the door to brain imaging. Overall, current evidence indicates that A β oligomers provide a substantive molecular basis for the cause, treatment and diagnosis of Alzheimer's disease.

Keywords

ADDLs; Antibodies; Diagnostics; Etiology; Immunotherapy; Signaling; Structure; Synapses; Therapeutics

Introduction

Clinical trials for Alzheimer's disease (AD) that target the buildup of amyloid beta (A β) have been a lingering disappointment. Lack of success for over a decade has fueled misgivings about the therapeutic value of A β -related targets, and even raised questions about whether A β pathology is the key to nerve cell damage and dementia onset. This may, however, be a case of throwing out the proverbial baby with the bathwater. More than 30 years' worth of evidence has established the critical involvement of A β in instigating AD, including the more recent discovery that a different type of mutation in APP, one that reduces A β levels, protects carriers from getting the disease [73]. Clinical failures can be attributed to bad timing, poor drugs, and perhaps most importantly, impacting the wrong targets [157]. Widespread studies since 1998 strongly suggest the correct targets comprise toxic amyloid β oligomers (A β O).

Development of the oligomer hypothesis

Although soluble oligomeric A β species were detected in AD brain tissue more than 20 years ago [42], their presence was regarded only as evidence of ongoing fibrillogenesis and not relevant to nerve cell damage and the onset of dementia. However, a different conclusion emerged when experimental methods were found that could give toxic solutions of A β that were fibril-free [131]. Soluble A β O, formed without fibrils using very low doses of A β , or through the chaperone-like action of clusterin, were discovered to be potent CNS neurotoxins [95]. A β O rapidly inhibited LTP in brain slices, and, with increased exposure, they accelerated nerve cell-specific death, through a signaling-dependent mechanism requiring the protein tyrosine kinase Fyn. Based on these findings, it was proposed that early memory loss in AD and the progressively catastrophic dementia were caused by neural signaling dysfunction triggered by soluble A β O [82, 95].

Over the last decade, the A β oligomer hypothesis has generated widespread interest, and numerous reviews have covered major milestones substantiating its applicability to AD [39, 60, 61, 86, 122, 139]. The A β O hypothesis has been described as a small conceptual revolution [60] and is widely regarded as accounting for the onset of neuron damage leading to AD (Fig. 1a). A β O have been shown to build up in AD brain in a manner distinct from amyloid plaques [76] and to accumulate in AD animal models [14, 17]. A β O from AD brain and synthetic A β O appear structurally equivalent [47, 76], they disrupt synaptic plasticity as well as learning and memory when injected into animal models [17, 175], their

emergence coincides with onset of memory dysfunction in Tg models [105], and antibodies against A β O rescue memory performance in those models [183, 194]. Mechanistically, A β O act like pathogenic gain-of-function ligands, targeting certain cells and synapses on those cells [91]. Although structural questions regarding the nature of toxic A β O species still are under rigorous investigation [5] and not all oligomers are active [16, 93], it has been established that brain-derived and synthetic A β O share similar toxicology [25, 84]. Moreover, as shown in Fig. 1a, b, the cellular damage that can be instigated by A β O extends to virtually all major aspects of AD neuropathology. Although not proven, and not uniformly accepted, there is a high probability that A β O play a critical role in instigating AD.

Our primary purpose is to focus on recent works and review issues being addressed in the current A β O literature. Given that over 1,200 articles have appeared in the last 3 years alone, it is unfortunate but inevitable that important works have not been included, and we regret the missed opportunities. Due to publication constraints, there is a significant amount of information that can be found in the supplementary material. Our review is organized according to the following themes—A β O etiology; the toxic mechanism; A β O structure and analytics; A β O-directed therapeutics; and A β O-directed diagnostics.

Etiology and mechanism

Why do A β O show up?

Remarkably little is known about the etiology of A β O accumulation in sporadic AD, which accounts for roughly 95 % of AD cases. A clue to onset may be the peculiar distribution of A β O seen in very early stages of pathology (Fig. 2). In a field of hundreds of neurons, only about a dozen show the presence of A β O which, as seen in the inset, distribute perisomatically. If we could understand what accounts for this cell-specific and sporadic distribution, we might have a better handle on the etiology of A β O.

It sometimes is said that AD manifests as multiple diseases. The etiology of A β O buildup may thus involve disparate factors, and in the long run, successful treatment might depend on knowing which etiological triggers are involved. Current investigations concern factors such as pathophysiological co-morbidities, toxic environments, and loss of natural defense mechanisms with aging. Environmental and behavioral factors, including diet choices, will be of particular interest because they can be corrected.

While a broader discussion of etiological factors in A β O buildup can be found in the supplementary material, one rapidly developing area of investigation concerns the defense provided by neuronal insulin signaling, and the relationship between A β O, diabetes, and resistance to insulin signaling in the AD brain. A detailed review of this relationship has recently become available [22]. One side of the story centers on defense against A β O: CNS insulin signaling serves to prevent A β O buildup [7] and to block A β O neurotoxic binding [23]. The other side of the story is the vulnerability of the mechanism itself to A β O toxicity: A β O impair insulin signal transduction on CNS neurons by blocking trafficking of insulin receptors to dendritic membranes [23] and inhibiting the critical effector IRS-1 [111]. By rendering neurons insulin-resistant, A β O provide a mechanism to explain why AD appears

to be a Type 3 diabetes [26, 27]. Consistent with results from cell biology, animals given ICV injections of A β Os show impaired brain insulin signaling and metabolism along with memory loss [57, 135]. This animal model appears to recapitulate insulin neuropathology in the AD brain [8]. Overall, a vicious cycle emerges. As A β Os increase due to impaired CNS insulin signaling, insulin signaling grows even weaker, due to the impact of the toxic A β Os (Fig. 3). Furthermore, when insulin receptors are down, GSK3 β activity is up, and this may be germane to pTau elevation [4]. Decreased CNS insulin signaling which appears to occur with age could tip the scales toward A β Os in the struggle for synaptic survival. The section later on Therapeutics discusses the targeting of CNS insulin signaling for AD treatment.

Are A β Os extracellular, intracellular, or both?

A persistent debate is whether A β Os accumulate and instigate neuronal damage extracellularly or intracellularly. The answer is especially relevant given that toxicity assays use exogenously added A β Os. Persuasive evidence has been obtained that supports each view. Subcellular distribution of brain A β Os at very early stages of pathology is consistent with extracellular association of A β Os with surface membranes (Fig. 2). Direct evidence for extracellular accumulation came from older measurements of A β Os in human CSF, which shows increased abundance in AD patients [45] (Fig. 4). A suggested prion-like spread of A β Os, while still being investigated [155], is consistent with an extracellular presence, and the buildup of A β Os in the medium of APP-transfected cells indicates a capacity for natural A β O secretion [17, 175]. The efficacy of antibodies in reducing pathology [132] and rescuing behavior, even in some cases as readily as 24 h [29] further substantiates with the existence of extracellular A β Os. Although antibodies can be internalized, this occurs after binding to cell surface epitopes. On the other hand, immunohistochemistry of many TG models show robust intracellular accumulation of A β Os (see, e.g., Fig. 4), and high-resolution EM studies of human samples show A β Os intracellularly at synaptic terminals [48]. Although A β Os could assemble from extracellular monomers, they also appear to be released from intracellular pools [176]. A β Os additionally appear to accumulate in AD astrocytes, although the form they take is uncertain [96], and it is evident that A β Os are taken up by microglia. Older evidence thus indicates that A β Os can occur in both intracellular and extracellular pools. The possibility that these pools undergo a dynamic exchange would reconcile both views [132].

Recent evidence for intracellular A β Os

Evidence for intracellular synthesis and uptake of A β Os continues to come from studies of human neuropathology and transgenic animal models. In human tissue, intracellular A β Os have been identified in cholinergic neurons, suggesting a role in cholinergic deficiency [128]. In Tg2576 mice, intraneuronal A β Os are associated with loss of MAP2 in dendrites and postsynaptic terminals [162], consistent with a previous report of synaptic pTau. The data suggest low MW A β Os precede high MW oligomer and plaque formation. Multiple studies suggest that aggregation and clearance of A β are influenced by ApoE isoforms [59, 154]. Co-culture and in vivo experiments demonstrate that ApoE, secreted by astrocytes, is essential for receptormediated uptake of A β by neurons. Results showed that a non-toxic

ApoE/A β interaction antagonist, A β 12–28P, blocked uptake and blocked synapse protein loss. The peptide was also protective in vivo [90].

Recent evidence for extracellular A β Os

In cell culture models, SH-SY5Y, +/– transfected with Swedish double mutant APP, showed intracellular accumulation of A β O in many membrane-bound organelles as well as cytosolic structures; further data indicate A β does not localize to particular organelles and is largely secreted from cells [196]. Overall results are consistent with the pool of extracellular A β Os originating from secreted A β Os as well as a pool that assembles from secreted monomer. Especially convincing new evidence for extracellular pools of A β Os comes from microdialysis experiments. Brain interstitial fluid from living mice showed an age and transgene-dependent presence of A β Os [164]. Acute inhibition of gamma-secretase caused A β O abundance to decrease, a key control that A β Os were derived from expected metabolic pathways. It has been noted in some experimental models (e.g., APP-transfected cell lines) that extracellular pools of A β Os are insensitive to secretase inhibitors [53]. The acute efficacy of therapeutic antibodies further supports the neurological significance of extracellular A β Os [29]. Antibodies against oligomers recently were shown to reduce A β Os and plaques and improve memory function [163]. Data were consistent with earlier conclusions that extracellular and intracellular A β O pools are dynamically related, potentially involving sortilin, and they also indicated that intracellular accumulation of A β Os is upstream of tau pathology. scFv antibodies against A β have been found to readily reach the brain following intranasal administration [13], and A β O antibodies delivered through intranasal administration were found to rescue performance on the Morris water maze paradigm [183].

Extracellular prion-like spread?

Data that A β Os can accumulate intracellularly and later be secreted are consistent with a suggested prion-like propagation of A β Os (for history of this idea, see [155]). Oligomers of other non-prion proteins (e.g., tauOs and synucleinOs) also have been reported to show prion-like behavior [55, 88]. Cell-to-cell transfer of A β Os has been seen using a donor–acceptor 3-D co-culture model. Transfer appears to be an early event that occurs before and is independent of cell degeneration [30]. Similar spreading is seen in astrocyte–neuron co-cultures where astrocytes are induced by endogenous A β 25–35 to make and secrete A β 42 [20]. Intraneuronal injection of A β Os into primary hippocampal neurons revealed neuron-to-neuron transfer that required direct cellular connections. Intracellular accumulation resulted in tubulin beading and endosomal leakage [127]. In vivo injections into the CA1 region of the hippocampus resulted in time-dependent effects on the expression levels of multiple genes distant from the injection site [34]. With respect to the prion-like potential of cell-to-cell transfer, it has been found that an unusual oligomeric species, large fatty acid-derived A β Os that are 12–18mers and form “off pathway”, can recruit A β 42 at expense of fibril formation and self-replicate [89]. Another unusual interaction occurs with synuclein, which can interact with A β and provide a seed for aggregation in vitro [134]. Oligomers were found to migrate from affected to unaffected neurons, where it was suggested they act as a template to promote formation of larger oligomers in a self-propagating manner [133]. Of particular interest, pyroglutamylated A β , which appears to be a pathophysiologically

important proteoform, makes especially toxic small oligomers when mixed with A β 42, more toxic than made by A β 42 alone. The mixed A β Os show tau-dependent toxicity, and they act as a template for restructuring of A β 42 into distinct small MW A β Os that propagate in prion-like manner [129].

Targeting synapses

If extracellular pools of A β Os are neurologically active, a key mechanistic question is whether they act with specificity—are particular cells targeted, and if so, how? Early studies showed that A β Os bind only to particular neurons, at most half those present in hippocampal cultures [16, 97]. Less binding occurs in cortical cultures and little to none in cerebellar cultures [97]. This pattern is in harmony with the region-dependent A β O toxicity seen in brain slice preparations [80]. Cell-specific binding correlates with toxic responses, e.g., stimulation of tau hyperphosphorylation [25].

Significantly, exogenous A β Os accumulate at synapses and in particular, at synaptic spines [47, 91], although presynaptic sites may also be targeted [62]. The ligand-like targeting of synapses is evident for both synthetic and brain-derived A β Os (Fig. 5). While additional targets may exist, this highly selective distribution is in harmony with rapid A β O-induced disruption of LTP and LTD [175, 177]. To account for the specificity of A β O targeting, it has been proposed that attachment is mediated by particular cell surface proteins that act as toxin receptors [95]. These receptors would be expressed only on certain cells and would act to convert binding into cell-damaging responses. This section reviews recent evidence regarding the toxin receptor hypothesis and the molecules that have been proposed as candidate receptors. How transduction of binding into toxicity takes place is considered in the next section.

Membrane proteins

The hunt for toxin receptors has been greatly invigorated by identification of cellular prion protein as a receptor candidate, first identified in a screen of a cDNA expression library [101]. Initial evidence strongly indicated binding to PrP was a key step in the mechanism of A β O toxicity [101] (for review, see [100]). Investigations of how externally oriented PrP might bring about intracellular damage indicate coupling to the protein tyrosine kinase Fyn (Fig. 6). This mechanism is consistent with early studies showing Fyn is essential for A β O-induced toxicity [15, 95]. Further details regarding A β O interactions with PrP, which remains somewhat controversial, can be found in the supplementary material.

A number of alternatives to PrP as A β O toxin receptors have emerged, giving what appears to be an oversupply of candidates (Fig. 7). Several prominent candidates are discussed further in the supplementary material. Some of the apparent oversupply may be due to involvement of candidates in responses to alternative forms of A β Os (next section; and see review by De Strooper [5]). It also may be that A β Os are promiscuous ligands, capable of interacting with different proteins expressed by different cells. Additionally, some candidates may have come from studies of A β O–membrane protein interactions that are significant but not as toxin receptors. Multiples types of A β O–membrane protein interactions can be envisioned. (1) A β Os could uniquely attach to one or a small set of high-

affinity binding proteins that act as specific toxin receptors. (2) A β O_s could attach to a variety of low-affinity toxin receptors and associate subsequently with co-receptors to create a multicomponent high-affinity complex. (3) A β O_s, attached to a toxin receptor or embedded within a complex, disrupt additional membrane proteins, whose downstream actions are key to neuronal damage.

Membrane lipids

A prominent alternative to the receptor hypothesis is that A β O_s insert directly into the lipid bilayer and disrupt membranes by acting as a pore [3, 76]. Much of the early support for this hypothesis came from experiments using artificial lipid bilayers. Structural consequences recently have been imaged by AFM, showing damage to POPC/ POPS lipid bilayers caused by A β 40 in different aggregation states [12]. A study examining the aggregation and lipid interaction properties of A β peptide fragments aggregated in the absence or presence of total brain lipid extract bilayers showed that some regions interact with and disrupt bilayers (e.g., A β 40) but others do not aggregate or interact with bilayers (e.g., A β 28 and A β 12–24) [186]. Some reports suggest that oligomers have more membrane affinity than monomers. This is evident in assays of non-neuronal as well as neuronal cells, suggesting that association in this assay is not receptor-dependent. A β O binding did not produce evidence of rapid cell damage [152]. Membrane insertion can be blocked by a pentapeptide from the glycine zipper region of the C-terminal of A β . This peptide abolishes synaptotoxicity [137]. Formation of an annular octameric channel of A β 22–35, which induces a zinc-sensitive Ca²⁺ influx, is enhanced by cholesterol [28], consistent with a possible lipid raft association. Support for raft domains as primary mediators of A β toxicity in AD comes from a study showing that rafts recruit A β O_s and that depletion of GM1 blocks interaction of A β O_s and their toxicity [37]. On the other hand, data suggest that a moderate increase in membrane cholesterol content may be protective against A β O toxicity [38]. The extensive literature concerning A β -lipid membrane interactions and molecular level membrane modeling has recently been reviewed [32], including the possible involvement of metals in the mechanism [179].

One of the difficulties encountered by the bilayer hypothesis for A β O attachment is its inability to account for specificity. Two neurons side-by-side can show completely different ability to accumulate A β O_s, one showing robust synaptic accumulation and the other showing virtually none [91]. Toxicity, measured by tau hyperphosphorylation, correlates with binding [91]. A second difficulty is an inability to account for binding saturability [91, 174]. It is possible, however, that rather than lipid bilayers, lipid rafts specific to particular synapses might play a role. It also has been hypothesized that A β O_s act through both lipids and proteins, forming pores at the membrane surface and binding as well to specific receptors to induce intracellular responses [69].

Transduction mechanism

How the initial attachment of A β O_s to neuronal membranes is transduced to instigate a toxic cascade is uncertain. A simple explanation would be that A β O_s are intrinsically toxic. It has long been suggested, e.g., that A β and its assemblies could instigate neuronal damage by chemically generating ROS [11], and such localized ROS generation is supported by recent

studies as well (e.g., [126]). A β O_s also appear capable of creating neurotoxic pores within membranes [3], with current observations continuing to support this concept [28, 99, 140]. However, observations that neurons show highly selective vulnerability to A β O binding and toxicity [91] seem more consistent with indirect mechanisms. Such mechanisms, building on the toxin receptor hypothesis, attribute A β O toxicity to agonist-like actions in which A β O_s perturb vital signaling pathways. Although some evidence indicates intracellular A β O_s could be responsible for elevated Ca²⁺, a critical link has been established between elevated ROS and A β O-stimulated Ca²⁺ through pathways involving metabotropic as well as ionotropic glutamate receptors (see supplementary material).

Protein redistribution: toxic highjacking

A significant mechanistic puzzle is how glutamate receptors are actually stimulated by A β O_s. Hypothetically, A β O_s might act as simple receptor agonists. The phenomenon, however, is clearly more complex, beginning with binding. Experiments have been done that track movements of individual, quantum dot-labeled A β O molecules on surfaces of live neurons [143]. At first, surface-attached A β O_s move freely, but after a few minutes they become immobile, often at synapses (Fig. 8). Significantly, mGluR5 receptors also become immobilized. The A β O_s and mGluR5s become co-clustered, and these clusters show a time-dependent increase in size. Hypothetically, this “receptor highjacking” could be a critical part of the transduction mechanism that leads to mGluR5 hyperactivity and excessive Ca²⁺ mobilization. This is strongly supported by experiments showing that crosslinking and clustering of mGluR5s by antibodies mimics the effects of A β O_s. Immobilization of A β O_s has been confirmed in recent single molecule tracking experiments [72, 125]. Interestingly, association of A β O_s with the surface was blocked by the presence of ATP-independent chaperones.

An interesting question is how PrP fits as a piece of the puzzle. PrPs and mGluR5s appear to be partners in at least some aspects of A β O toxicity [170]. It is known that PrP abundance increases at the surface in response to A β O_s [6]. Whether the anchoring of mGluR5s leads to a magnet-like redistribution of PrPs is possible but unknown. The ability of PrP to organize membrane domains [6, 151] may play a role, with lateral interactions involving a number of proteins that come together to create a potential toxicity domain (Fig. 8). This scaffolding effect can be construed as analogous to formation of focal contacts, but with pathogenic consequences when A β O_s become attached. Not only Ca²⁺ but cAMP levels [24, 156] could be disrupted. It is intriguing that once neurons have reached a fully differentiated state, PrP can enzymatically be removed with little or no impact on A β O accumulation in hot spots and synapses [180].

The current bottom line is that only little is known about how attachment of A β O_s to neurons and other brain cells is transduced into pathogenic signaling. On the other hand, a wealth of information exists regarding a more straightforward question—what happens downstream from the initial transduction event? A prominent example is the upstream role of A β O_s in instigating tau pathology. As recently demonstrated, tau hyperphosphorylation and mis-sorting induced by A β O_s is a significant factor in generating diseased neurons (Fig. 9). This pathway and others are considered in detail in the Supplementary Material.

Structure

Which forms of A β O are responsible for instigating AD nerve cell damage is a question of continuing interest [5]. A β assembly pathways lead to different outcomes (Fig. 10), and this also is true for assembly pathways that lead to A β O. As found a decade ago in vitro [16] and in vivo [105], not all A β O are toxic or neurologically active. Overall, the goal is to obtain structure for native, undenatured disease-relevant A β O species obtained under pathophysiological conditions.

Recent studies have substantiated the influence of structure on oligomer cytotoxicity [161], which is consistent with the specificity of action discussed above. A β is a member of the class of proteins known as intrinsically disordered proteins (IDPs)—proteins that lack a stable tertiary structure in physiological conditions [60], and A β conformation is highly dependent on its environment [85]. Equilibrium is constantly being reestablished, making it extremely difficult to discern the sizes and abundance of each oligomer present [60, 106]. Methodology itself, including both preparative and analytical methods, influences the outcome. It is difficult to investigate A β O under pathophysiologically relevant conditions, which themselves are hard to define. Previous investigations often used conditions that alter structure (such as incubations in SDS) or employed insensitive analytical methods requiring high levels of A β O, at concentrations that influence structure. Supplementary material accompanying this article gives an overview of recent approaches that may be more promising (preparations; immunochemical detection; biochemical analytics; mass spectroscopy; NMR; imaging; X-ray analysis; and molecular dynamic modeling). Comprehensive reviews of A β O methodology are available and described in the supplementary material.

Several articles provide up-to-date overviews of oligomeric structures [5, 60, 77]. Although a bit simplistic, species have been classified by size (low- n oligomers, 2–4mers; high- n oligomers ~12–48mers; and megamers, indefinitely large in size) and by shape (globular, prefibrillar, and annular). It remains uncertain if there is one species of oligomer that uniquely provides a molecular basis for the cause, treatment and diagnosis of AD or whether multiple species are involved. An interesting recent study suggests the latter [41]. In this study, synthetic A β O were separated into low molecular weight (LMW) and high molecular weight (HMW) species. Injected into brain, LMW oligomers induced a rapid, persistent impairment of memory associated with decreased hippocampal synaptophysin and GluN2B. HMW oligomers induced reversible memory impairment associated with induced oxidative stress but not synapse pathology. Memantine protected against the effects induced by the HMW oligomers, but not against the LMW oligomer. Although not in agreement with earlier findings from cell biology [92], which concluded that HMW A β O caused synaptic damage, the findings move the field closer to the goal of reconciling differing observations concerning structure and function. Various aspects of A β O structure recently under investigation are considered below as well as in the supplementary material.

Submolecular domains

A number of studies have investigated domains within the sequence of A β for their contributions to structure. Smaller A β O (1–2 nm in size) are highly immunogenic, more so

than larger oligomers, because of the exposed nature of their N-terminal [21]. Epitope mapping shows the N-terminus to be immunodominant for MAb production. The N-terminal tail (residues 1–9) of A β 40 oligomers, investigated by rapid fluorescence technology and 2-dimensional solid state NMR, also shows great influence over the affinity of oligomers for membranes; the turn region (residues 22–29) additionally influences membrane association. Notably, 10 of 11 FAD A β mutants map to these two regions [153]. A toxic turn at positions 22, 23 has been related to the ER stress marker GRP78 [160] and potentially is associated with ROS generation [65]. The nearby Gly25-Ser26 dipeptide, studied using synthetically modified A β peptide, appears critical for A β 42 oligomerization [149, 150]. Comparison of toxic and non-toxic A β Os indicates toxicity increases with the extent of solvent exposure of two hydrophobic domains (aa 16–22 and 30–42), reflecting the importance of conformation in toxicity [93]. Computational models indicate the hydrophobic surfaces of pore-forming A β Os promote insertion into membrane [70], while modeling and experimental studies indicate a C-Terminal turn at Val36-Gly37 (present in A β 42, not A β 40) promotes β -pleated sheet formation, rather than the coil seen in A β 40 [150]. The importance of the beta-pleated sheet is indicated by the ability of the breaker peptide KLVFFK(6) to inhibit A β O formation at substoichiometric doses [193]. β -sheets that are antiparallel are evident in toxic A β 42Os examined by X-ray diffraction [52], and these, when incubated with an abiotic cyclic d,l- α -peptide, are converted to a non-toxic parallel β -structure [145]. Formation of toxic beta sheet-rich A β Os is enhanced when monomeric A β 40 inserts into cell surface membranes, which can be prevented by interactions with curcumin, a treatment that prevents the toxic effects of Ca²⁺ influx [166].

Two major studies have emphasized the importance of out-of-register beta sheets [cylindrins]. These are formed from six antiparallel A β protein strands, as seen via X-ray derived atomic analysis [94]. It has been suggested that cylindrins might be part of a toxic amyloid pathway that is distinct and more energetically favored than the in-register amyloid pathway [109].

Exogenous factors influencing oligomerization

The discovery that oligomeric A β can be a potent CNS neurotoxin arose from studies of the interaction between A β and the chaperone-like action of clusterin/apoJ [95]. Interactions with other proteins are now under study. Interestingly, PrP acts similarly to apoJ. At a substoichiometric 1/20 ratio, PrP traps A β in an oligomeric form and inhibits fibril formation. The A β Os are in an antiparallel beta sheet conformation, unlike fibrils, and bind an A β O-specific antibody. The A β binding site involves aa 95–113 of PrP [187]. It also has been suggested that transglutaminase (Tg) could play a role in the initiation and development of A β aggregates [181]. Some protein interactions appear protective. α -Synuclein, e.g., decreases A β 42 oligomers and also is neuroprotective by stimulating the PI3K/Act cell survival pathway [144].

A significant interaction takes place between A β and A β fibrils themselves [18]. A kinetic study using selective radiolabeling and cell viability assays has found that A β Os form following critical accumulation of amyloid fibrils. The fibrils catalyze a secondary nucleation reaction which gives rise to the toxic A β Os. Formation of toxic A β Os from

monomers through a fibril-catalyzed secondary nucleation reaction thus couples growth of insoluble amyloid fibrils to the generation of diffusible oligomers. This mechanism is consistent with the halos of A β O surrounding dense core plaques. The possibility exists that A β O deposits in the brain at loci that lack associated Thioflavin S (thioS) reactivity nonetheless contain trace amounts of fibrillar amyloid [87, 174]. An implication of this fibril-catalyzed mechanism is that perturbation of the secondary nucleation pathway could be an effective strategy to control the proliferation of neurotoxic A β 42 oligomers. These findings are intriguing in light of the correlation between A β O and amyloid plaques in cognitively impaired but not in cognitively normal individuals [36].

Divergence of assembly pathways

An emerging concept is that self-association of A β proceeds along divergent paths, one toward oligomers and the other toward fibrils [173, 189]. Biophysical analysis shows there are structural similarities and differences between A β O and fibrils and that, while common β -strand conformations form early, oligomers and fibrils differ in schemes of intermolecular organization [165]. The kinetics of fibril formation suggests three phases: early oligomerization, an intermediate phase, and growth, with conformational change a key rate-limiting step [44]. The conformation of protofibrillar intermediates may be kinetically stable [51]. Existence of pathway differences between oligomer and fibril formation has been suggested from experiments using small organofluorine compounds to disrupt A β self-assembly [167]. Also, in addition to secondary nucleation, A β O formation can occur through a nucleated polymerization, consistent with alternative assembly pathways; the form with a toxic turn at aa22–23 appears early in AD, prior to memory loss [160]. Generation of two types of A β O was further indicated by results with oligomer-specific monoclonal antibodies, which reduced plaque load, tau phosphorylation, and behavior deficits [142]. Dual assembly pathways giving extended versus compact oligomers of A β 40 were found to be influenced by metal ions, which stabilized the compact form [159]. Different conformations for assemblies of A β 15–23 peptides were found to depend on the method of analysis [71], while diversity of A β dimers results in dual pathways that lead to annular oligomers or fibrils [168].

Divergence of assembly pathways begins virtually as soon as A β is put in solution, and the initial products are separable after only several minutes [173]. Fractionation in detergent-free buffer shows that A β O greater than 50 kDa maintain their oligomeric state with continued incubation, while smaller A β O show a propensity to form large aggregates and fibrils. Significantly, examined by SDS-PAGE, the early stage large and small A β O are indistinguishable, underscoring the importance of analytics carried out under conditions that preserve native, pathophysiologically relevant structure. It is interesting that subpopulations are evident even within the larger A β O. scFv antibodies target a small subset of A β O that prominently attach to synapses. Polymorphic oligomerization may be a general phenomenon, as alpha-synuclein under conditions that promote amyloid fibril formation generates two well-defined oligomeric species [110]. In analogy with prion species, these different α -synuclein oligomers have been referred to as strains [54].

Therapeutics

A recent review has laid out the case for exploiting A β O as therapeutic targets [61]. The failure of clinical trials that have targeted A β in general do not negate the value of approaches that target A β O in particular. Whether A β O are present and have a physiological role in normal brain is not known, but it appears worthwhile to prevent damage caused by excessive A β O levels. In animal models, when A β O levels are brought down, normal behavior goes up [104]. While targeting A β O seems a rational strategy, there may be no single silver bullet, and what may be required, given the difficulties in contending with A β O toxicity [148], are combinatorial approaches. Different treatments, moreover, may be needed to contend with different etiologies. A β O instigated by diabetes may require different treatments than those instigated by mechanical injury or hypercholesterolemia. Recent discovery efforts considered below concern vaccines that target A β O, on targeting the relationship between A β O, toxin receptor antagonists, inflammation and insulin signaling, and on intriguing findings from behavior modification. Overall, there is an extensive effort underway to find the means to prevent A β O-induced brain damage. The supplementary material summarizes recent attempts to identify natural products and small organic molecules that block accumulation or counter the effects of toxic A β O.

Immunotherapy—A β O antibodies

Two of the most prominent Alzheimer's therapeutic antibodies tested to date have been disappointing, but they are not selective for A β O. Solanezumab, derived from the murine antibody 266, has high preferential affinity for monomer [158]. Removing the precursor to A β -derived toxins would require more antibody than targeting the toxins themselves, but modest benefits have nonetheless appeared in the latest analysis [98, 108]. Bapineuzumab, which does bind A β O and has low affinity for monomers, also attaches to amyloid fibrils [78]. Off-target specificities may account for lack of efficacy of each, and also the micro-hemorrhages caused by bapineuzumab, which can bind vascular amyloid.

Given the promise yet disappointment of A β vaccines designed to eliminate amyloid plaques, there have been efforts to obtain antibodies selective for A β O [75, 96, 102]. The value of A β O as targets for immunotherapy and the status of clinical candidates have been recently reviewed [49, 124]. Although a caveat has suggested that antibodies bound to A β O might activate microglia and potentiate A β O neurotoxicity [120], such toxicity is not in harmony with numerous reports of neuroprotection [49]. With respect to safety, an IgG4 antibody against A β counters the impact of A β O in animal models more safely than IgG1 antibodies, and it shows no vasogenic edema in phase I clinical trials [1]. A β O exist in forms that assemble into fibrils and those that do not, and these forms can be distinguished by antibodies [75]. In animal models, antibodies that target non-fibrillar A β O improve behavior and also reduce the amyloid load [142], consistent with a dynamic equilibrium between A β O and amyloid plaques. These antibodies reduce tau pathology, also seen earlier with the broader-based A11 oligomer antibody [132]. Another A β O antibody (72D9) sequestered both extracellular and intraneuronal A β O [115]. Sequestering A β O in older Tg mice attenuates synapse loss near plaques and abolishes loss further away [31]. This location-dependent efficacy is consistent with the proposed capacity of plaques to act as a

reservoir that releases A β Os [86]. In a new approach for delivery, A β O antibodies have been administered intranasally, which was found to rescue Morris water maze performance [183]. The therapeutic potential of oligomer-specific monoclonal antibodies for AD therapeutics has led to development of humanized forms. An antibody described as targeting protofibrillar A β Os, promoted by the Arctic mutation [74], reduced A β Os in the brains and CSF of the mouse model with no impact on A β monomers [169]. The humanized version (BAN2401) has obtained favorable safety profile in Phase 1 clinical trials. The recently described humanized mAb ACU-193 has high affinity for A β Os with very low affinity for monomers and fibrils [49, 61]. Although effective in model systems, ACU-193 has not been tested in humans.

Single chain antibodies have been identified that target A β Os with great specificity [178]. One human scFv, specific for a small subset of synthetic A β Os [173], greatly reduces A β O binding to synapses despite targeting a negligible fraction of the total A β O pool. Another A β O-specific scFv (h3D6), given in a single intraperitoneal injection to an AD mouse, was found to reduce behavioral deficits [46]. These studies also showed that h3D6 reduced A β O levels in cortex and olfactory bulb but not hippocampus, although it is possible that hippocampal A β Os were neutralized but not eliminated, and reduced nerve cell death in cerebellum. Methods to prepare human Fab phage display libraries and screen for A β O-specific antibodies have been described [188]. Recent developments regarding active vaccines and autoantibodies are presented in the supplementary material.

Toxin receptor antagonists

As discussed above, the identity of A β O toxin receptors is uncertain, but even without definitive receptor identification, it is possible to screen for antagonists using unbiased binding assays. A cell-based assay led to a small organic molecule blocker of A β O binding with potential therapeutic value [66, 67]. The antagonist appears to target Sigma2/ PGRMC1 receptors and it blocks A β O binding and synaptotoxicity. Another unbiased high-throughput screening approach, which uses detergent-extracted synaptic membrane proteins reconstituted in soluble nanoscale membranes, has also shown that small organic molecules can block the protein–protein interactions between A β Os and their receptors (Fig. 11). Interestingly, the A β O antagonist had previously been found to rescue performance in an AD mouse model, although its relation to A β Os had not been determined [103].

Insulin signaling and TNF- α

The relationship between A β Os and impaired brain insulin signaling, although complex (Fig. 3) has helped stimulate efforts to enhance brain insulin signaling for therapeutics. Interest in this possibility already was kindled by earlier work, and clinical trials using intranasal insulin have shown indications of positive benefits [19]. Because A β Os themselves can impair insulin receptor function [23], indirect approaches also are being explored. The diabetes drug rosiglitazone, which lowers A β O binding in culture [23], has been found to rescue synapses and plasticity in vivo via a PPAR gamma pathway [184]. Use of d-chiro-inositol, which also enhances insulin signaling and is now available as an over-the-counter product, also prevents A β O binding [138]. Exendin, an analog of GLP-1 that can substitute for direct insulin signaling, has been shown to have major beneficial effects in

multiple preclinical models [8, 111]. Liraglutide, another analog of GLP-1 that reduces A β O impact, is now in clinical trials [117].

An interesting development is the apparent involvement of TNF α as an effector of A β O toxicity, making this inflammatory agent a potentially valuable therapeutic target [111]. AD patients show elevated TNF α in cortex, hippocampus and CSF. Sequestering TNF α was earlier reported to be beneficial to AD patients [50], and, although this approach has not been pursued in the clinic, evidence from AD mouse models suggests potential efficacy [68, 116]. An AD model was found to manifest high levels of TNF α at an early age, when A β O were present but plaques had not yet formed [43]. Chronic treatment with small molecule inhibitors of TNF α improved working memory performance and brought about reduced brain levels of TNF α mRNA and protein. In culture, exposure of microglia to A β O leads to increases in TNF α , along with other inflammatory factors [79]. Donepezil surprisingly suppresses these cellular responses, and in A β O-injected mice, it inhibits gliosis and rescues memory function. Curcumin, an ingredient in turmeric that is neuroprotective against A β O in various models [185], can act to block TNF α action and production [2]. Another natural product found in ginger (6-shogaol) reduces glial cell activation and memory impairment in A β O-injected mice [119]. Mechanistically, TNF α has been identified as critical to A β O-induced insulin resistance, which manifests in IRS-1 inhibition [111] as well as impaired insulin receptor trafficking and surface down-regulation [23, 195]. Two downstream mediators of TNF α have been identified—dsRNA-dependent protein kinase (PKR) and eukaryotic translation initiation factor 2 α (eIF2 α -P), which is phosphorylated by PKR [111]. Both effectors of TNF α are elevated in AD brains and in AD animal models, including monkeys given A β O by icv injections. A β O coupling to eIF2 α -P and cognitive impairment is lost in PKR(–/–) and TNFR1(–/–) mice, establishing that proinflammatory signaling mediates A β O-induced IRS-1 inhibition and PKR-dependent synapse and memory loss.

Diet, exercise and enriched environments

Slowing the onset and progression of A β O pathogenesis by behavioral modifications (e.g., changes in diet, exercise or environmental richness) presents an intriguing supplement to pharmaceutical approaches. Several articles above indicate diets rich in compounds such as DHA, curcumin, and ginger would be of value, while diets high in fats or cholesterol would be harmful, fostering A β O accumulation [172]. Effects of diet on cognitive aging have been studied in carnivores, which develop cognitive decline and progressive accumulation of oxidative damage with age. When maintained on an antioxidant diet that includes fruits and vegetables, aged animals show cognitive improvement associated with improved mitochondrial function. Whether such diets benefit non-carnivores such as rabbits, which develop A β O in response to diabetes [7], is not known.

Exercise increases BDNF levels [64], which are decreased by A β O [136]. The overall effects of exercise are complex, especially the relationship between exercise and diet. High-fat diet worsens cognitive function in amyloid precursor protein (APP) transgenic mice, but exercise lowers A β deposition and memory deficit [112]. Exercise in an enriched environment rescues diet-induced A β deposition and memory deficit; however, consumption

of a high-fat diet after 10 weeks of exercise reversed the benefits, leading to increased levels of A β O and impaired memory performance. In aging humans, there is a correlation between reduced onset of AD and elevated blood oxygen, and this may likely be a consequence of the effects of exercise [10].

Intriguingly, enriched environments rescue cognitive function in animal models, a consequence separate from the effects of exercise [107]. The physiology involves enhanced long-term potentiation through activation of beta2-adrenergic receptors and cAMP/PKA signaling. This signaling prevented inhibition of LTP by human brain-derived A β O.

A diet with a beta-adrenergic agonist in lieu of environmental enrichment also was protective. The conclusion that enriched environments mitigate A β O synaptotoxicity by activating beta-adrenoreceptor signaling substantiates the value of cognitive novelty during aging, perhaps in tandem with oral beta-adrenergic agonists. At an additional level, it has been found that enriched environments increase synthesis of the A β -degrading enzyme neprilysin and decreases the abundance of brain A β O, accompanied by an upward shift of the cortical excitation/inhibition balance [114].

Combination therapy

AD is a complex and multi-faceted disease with various etiological origins that give rise to various co-morbidities. It has been suggested that therapeutic success may therefore depend on combination therapies, such as enhanced insulin signaling in tandem with A β O-specific vaccines [23]. Combination therapies might even be tailored to etiology—AD onset coupled to diabetes might be treated differently than onset coupled to high cholesterol. Use of multiple antibodies for immunotherapy also is a possibility. A new antibody target that has recently emerged is Dickkopf-1 (Dkk1), a secreted Wnt antagonist [141]. Acute treatment of brain slices with A β O induces Dkk1, expression of which is elevated in brains of AD patients and in AD transgenic mouse models. In brain slices, Dkk1-neutralizing antibodies suppress A β -induced synapse loss. Roles of TNF α and tau in A β O-instigated pathogenesis suggests further that antibodies targeting these effectors, along with those targeting A β O, might significantly enhance outcomes [9, 182].

Diagnostics

There is no single rigorous assay for AD. Current recommendations for diagnosing AD include MMSE evaluations, CSF assays for tau and A β , MRI for brain volume, and PET scans for A β plaques and/or glucose metabolism in the brain. When used in various combinations, the tests are relatively accurate for diagnosing AD and determining disease severity. Given the role of A β O in pathogenesis, it would be of great value to also detect and measure them. A β O accumulate early, perhaps the first indicator of AD pathology, so A β O assays would be useful for catching disease onset [91, 121]. And, because A β O are instigators of critical brain cell damage, their measurement could track the efficacy of disease-modifying treatments [174] (for reviews see [81, 84]). With new evidence that prefibrillar pathological forms of tau can be detected in MCI and early AD [123], it may be that combined assays of A β O and tauO will provide definitive tests of disease onset and progression.

CSF assay

New assays have been developed to measure A β O_s in CSF, extending early efforts that introduced CSF-A β O_s as AD biomarkers [45, 56]. Results, however, have varied widely. CSF-A β O_s in AD have been reported to be elevated, decreased, unchanged, or not measureable. Nonetheless, the positive findings suggest cautious optimism (see details in supplementary material). Of particular interest are indications that A β O assays may detect individuals with MCI who have high risk of developing AD. An oligomer antibody-based ELISA found that A β O levels were elevated in AD that later converted to AD; although the assay showed very tight correlation with synthetic A β O_s, a large overlap between patient groups limits its current diagnostic potential [63]. Although ELISAs are regarded to be sensitive, the requisite limits of detection for CSF assays are likely to be more demanding. In assays looking specifically at A β trimers and 12-mers (A β *56), data indicated that these species (both of which increased with age) were elevated in cognitively intact older adults who were at risk for AD [58]. Prior to overt symptoms, one or both of the A β O_s, but not fibrillar A β , correlated with tau. This correlation diminished when AD advances to symptomatic stage. It also has been reported that annular A β O_s appear in a small test of presymptomatic FAD carriers [146]. These findings suggest that ultimately it could be possible to prevent progression to AD by knowing which A β O species to target in asymptomatic subjects.

Interestingly, the possible use of plasma A β O levels is suggested from results of a two-target assay measuring A β O_s and soluble TNF-R [192]. The large trial assayed plasma from 120 controls, 32 amnesic mild cognitive impairment (aMCI) patients, and 90 mild AD patients. Increases in A β O_s and soluble TNF-R levels accurately differentiated mild AD patients from control subjects, and to some extent from aMCI patients, suggesting intriguing potential as diagnostic biomarkers.

Imaging

Precedent for use of brain imaging to detect molecular pathology in AD patients has been established by the revolutionary use of PiB to quantify amyloid plaque load [83]. While brain damage during onset and progression of AD can be assessed by MRI for brain volume and FDG-PET for neuronal health, PiB analysis of amyloid plaques has been especially encouraging because it establishes precedent for uncovering important molecular pathology long before clinical signs of AD [33, 35]. However, it is A β O_s rather than amyloid plaques that now are considered the agents of AD onset.

Approaches to target A β O_s and other very early biomarkers such as tau-O_s are beginning to be described. Pronucleon imaging, using engineered peptides that give readout when associated with beta-rich fibers, has the ability to identify plaques throughout the brain of transgenic mice in vivo and plaque-like structures in Tg mouse brain sections, but it also is regarded as having the potential to detect A β O_s [130]. A novel PET probe has been introduced that combines tracer with specific monoclonal antibodies against A β protofibrils. The probe produces a signal in A β PP Tg mice that were devoid of A β plaques. It locates diffusely within the parenchyma and in older animals can localize around senile plaques (e.g., Fig. 2; [113]). This distribution of A β O_s as a halo around dense cores is well known

(see, e.g., Fig. 12a). Another antibody-derived PET probe, using the 6E10 N-terminal directed A β antibody, was delivered intravenously and found capable of distinguishing AD mice from controls [118]. Use of probes based on antibodies has been extended to molecular MRI, which could provide better spatial resolution and safety than PET [147]. An A β O-targeted MRI probe has been developed using an A β O antibody coupled to a strong T2 contrast agent [174]. These MRI-antibody probes, when delivered intranasally to bypass the blood brain barrier, can reach their hippocampal targets within 4 h and distinguish AD mice from controls (Fig. 12b). Diagnostic results are consistent with the therapeutic benefits found with intranasal delivery of the same antibody [183].

Conclusion

Over the past 3 years, well over 1,000 papers have investigated the hypothesis that nerve cell damage leading to Alzheimer's dementia is instigated by toxic A β Os, a structural archetype that now appears relevant to dozens of diseases of fibrillogenic proteins. New results have substantiated earlier findings that persons with AD, as well as AD animal models, manifest the presence of toxic A β Os. Experiments with multiple in vitro and in vivo models have elucidated the broad pathogenic impact of A β Os, and they have provided significant advances into how cells are targeted and the mechanisms that lead to cell damage. The puzzle of disease-relevant A β O structure is being approached through application of powerful new technologies and the potential of targeting A β Os for early diagnostics and monitoring disease control is beginning to be broached. First insights are being garnered into the etiology of A β O buildup, which ultimately may inform therapeutic strategies that couple the targeting of A β Os to treatments tailored to etiological triggers. Multiple strategies are being explored that target A β Os for therapeutics, including development of A β O-specific antibodies, toxin receptor antagonists, oligomerization blockers and disruptors, and enhanced neurotrophic signaling by behavioral modification as well as pharmacology.

These efforts reflect a widely held belief that A β Os provide a unifying molecular basis for the cause, diagnosis and treatment of AD. Nonetheless, there is no consensus of agreement concerning the A β O hypothesis. Proof demands that disease-modifying AD therapeutics be achieved by targeting of toxic A β Os. This is a significant challenge, as has been discussed. While the new A4 and DIAN trials are promising in their design to treat patients before symptoms develop, what still is missing are trials that specifically target A β Os, the toxins that many investigators think are the true culprits.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We would like to thank Erika Cline, Henry Weiss, and Kyle Wilcox for their editorial contributions. We would also like to thank our supporters: the National Institutes of Health (AG022547, AG029460 and AG045637), Baxter Healthcare, Inc., and the Northwestern University Clinical and Translational Sciences Institute.

Abbreviations

Aβ	Amyloid beta
AβO	Amyloid beta oligomer
AD	Alzheimer's disease
AFM	Atomic force microscopy
CNS	Central nervous system
CSF	Cerebrospinal fluid
FAD	Familial Alzheimer's disease
HMW	High molecular weight
IDP	Intrinsically disordered proteins
LMW	Low molecular weight
LTP	Long-term potentiation
MAb	Monoclonal antibody
MCI	Mild cognitive impairment
MRI	Magnetic resonance imaging
MW	Molecular weight
PET	Positron emission tomography
PrP	Prion protein
scFv	Single chain variable fragment

References

1. Adolfsson O, Pihlgren M, Toni N, Varisco Y, Buccarello AL, Antonello K, Lohmann S, Piorkowska K, Gafner V, Atwal JK, Maloney J, Chen M, Gogineni A, Weimer RM, Mortensen DL, Friesenhahn M, Ho C, Paul R, Pfeifer A, Muhs A, Watts RJ. An effector-reduced anti-beta-amyloid (A β) antibody with unique abeta binding properties promotes neuroprotection and glial engulfment of A β . *J Neurosci Off J Soc Neurosci*. 2012; 32(28):9677–9689. doi:10.1523/jneurosci.4742-11.2012.
2. Aggarwal BB, Gupta SC, Sung B. Curcumin: an orally bioavailable blocker of TNF and other pro-inflammatory biomarkers. *Br J Pharmacol*. 2013; 169(8):1672–1692. doi:10.1111/bph.12131. [PubMed: 23425071]
3. Arispe N. Architecture of the Alzheimer's A β ion channel pore. *J Membr Biol*. 2004; 197(1): 33–48. doi:10.1007/s00232-003-0638-7. [PubMed: 15014916]
4. Bartl J, Meyer A, Brendler S, Riederer P, Grunblatt E. Different effects of soluble and aggregated amyloid β 42 on gene/protein expression and enzyme activity involved in insulin and APP pathways. *J Neural Trans Vienna Austria*. 1996. 2013; 120(1):113–120. doi:10.1007/s00702-012-0852-5.
5. Benilova I, Karran E, De Strooper B. The toxic A β oligomer and Alzheimer's disease: an emperor in need of clothes. *Nat Neurosci*. 2012; 15(3):349–357. doi:10.1038/nn.3028. [PubMed: 22286176]
6. Beraldo FH, Arantes CP, Santos TG, Machado CF, Roffe M, Hajj GN, Lee KS, Magalhaes AC, Caetano FA, Mancini GL, Lopes MH, Americo TA, Magdesian MH, Ferguson SS, Linden R, Prado

- MA, Martins VR. Metabotropic glutamate receptors transduce signals for neurite outgrowth after binding of the prion protein to laminin gamma1 chain. *FASEB J Off Publ Fed Am Soc Exp Biol.* 2011; 25(1):265–279. doi:10.1096/fj.10-161653.
7. Bitel CL, Kasinathan C, Kaswala RH, Klein WL, Frederikse PH. Amyloid-beta and tau pathology of Alzheimer's disease induced by diabetes in a rabbit animal model. *J Alzheimer's Dis.* 2012; 32(2): 291–305. doi:10.3233/jad-2012-120571. [PubMed: 22785400]
 8. Bomfim TR, Forny-Germano L, Sathler LB, Brito-Moreira J, Houzel JC, Decker H, Silverman MA, Kazi H, Melo HM, McClean PL, Holscher C, Arnold SE, Talbot K, Klein WL, Munoz DP, Ferreira ST, De Felice FG. An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease-associated Abeta oligomers. *J Clin Investig.* 2012; 122(4):1339–1353. doi:10.1172/jci57256. [PubMed: 22476196]
 9. Boutajangout A, Wisniewski T. Tau-based therapeutic approaches for Alzheimer's disease—a mini-review. *Gerontology.* 2014; 60(5):381–385. doi:10.1159/000358875. [PubMed: 24732638]
 10. Bullain SS, Corrada MM, Shah BA, Mozaffar FH, Panzenboeck M, Kawas CH. Poor physical performance and dementia in the oldest old: the 90 + study. *JAMA Neurol.* 2013; 70(1):107–113. doi:10.1001/jamaneurol.2013.583. [PubMed: 23090391]
 11. Butterfield DA, Castegna A, Lauderback CM, Drake J. Evidence that amyloid beta-peptide-induced lipid peroxidation and its sequelae in Alzheimer's disease brain contribute to neuronal death. *Neurobiol Aging.* 2002; 23(5):655–664. [PubMed: 12392766]
 12. Canale C, Seghezza S, Vilasi S, Carrota R, Bulone D, Diaspro A, San Biagio PL, Dante S. Different effects of Alzheimer's peptide Abeta(1–40) oligomers and fibrils on supported lipid membranes. *Biophys Chem.* 2013; 182:23–29. doi:10.1016/j.bpc.2013.07.010. [PubMed: 23998637]
 13. Catepoel S, Hanenberg M, Kulic L, Nitsch RM. Chronic intranasal treatment with an anti-Abeta(30–42) scFv antibody ameliorates amyloid pathology in a transgenic mouse model of Alzheimer's disease. *PLoS One.* 2011; 6(4):e18296. doi:10.1371/journal.pone.0018296. [PubMed: 21483675]
 14. Chang L, Bakhos L, Wang Z, Venton DL, Klein WL. Femtomole immunodetection of synthetic and endogenous amyloid-beta oligomers and its application to Alzheimer's disease drug candidate screening. *J Mol Neurosci MN.* 2003; 20(3):305–313. doi:10.1385/JMN:20:3:305.
 15. Chin J, Palop JJ, Yu GQ, Kojima N, Masliah E, Mucke L. Fyn kinase modulates synaptotoxicity, but not aberrant sprouting, in human amyloid precursor protein transgenic mice. *J Neurosci Off J Society Neurosci.* 2004; 24(19):4692–4697. doi:10.1523/jneurosci.0277-04.2004.
 16. Chromy BA, Nowak RJ, Lambert MP, Viola KL, Chang L, Velasco PT, Jones BW, Fernandez SJ, Lacor PN, Horowitz P, Finch CE, Krafft GA, Klein WL. Self-assembly of Abeta(1–42) into globular neurotoxins. *Biochemistry.* 2003; 42(44):12749–12760. doi:10.1021/bi030029q. [PubMed: 14596589]
 17. Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, Selkoe DJ, Ashe KH. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. *Nat Neurosci.* 2005; 8(1):79–84. doi:10.1038/nn1372. [PubMed: 15608634]
 18. Cohen SI, Linse S, Luheshi LM, Hellstrand E, White DA, Rajah L, Otzen DE, Vendruscolo M, Dobson CM, Knowles TP. Proliferation of amyloid-beta42 aggregates occurs through a secondary nucleation mechanism. *Proc Natl Acad Sci USA.* 2013; 110(24):9758–9763. doi:10.1073/pnas.1218402110. [PubMed: 23703910]
 19. Craft S, Baker LD, Montine TJ, Minoshima S, Watson GS, Claxton A, Arbuckle M, Callaghan M, Tsai E, Plymate SR, Green PS, Leverenz J, Cross D, Gerton B. Intranasal insulin therapy for Alzheimer disease and amnesic mild cognitive impairment: a pilot clinical trial. *Arch Neurol.* 2012; 69(1):29–38. doi:10.1001/archneurol.2011.233. [PubMed: 21911655]
 20. Dal Pra I, Chiarini A, Gui L, Chakravarthy B, Pacchiana R, Gardenal E, Whitfield JF, Armato U. Do astrocytes collaborate with neurons in spreading the “infectious” Abeta and tau drivers of Alzheimer's disease? *Neurosci Rev J Bring Neurobiol Neurol Psychiatr.* 2014 doi: 10.1177/1073858414529828.
 21. Dalgiediene I, Lasickiene R, Budvytyte R, Valincius G, Morkuniene R, Borutaite V, Zvirbliene A. Immunogenic properties of amyloid beta oligomers. *J Biomed Sci.* 2013; 20:10. doi: 10.1186/1423-0127-20-10. [PubMed: 23432787]

22. De Felice FG, Lourenco MV, Ferreira ST. How does brain insulin resistance develop in Alzheimer's disease? *Alzheimer's Dement J Alzheimer's Assoc.* 2014; 10(1 Suppl):S26–S32. doi: 10.1016/j.jalz.2013.12.004.
23. De Felice FG, Vieira MN, Bomfim TR, Decker H, Velasco PT, Lambert MP, Viola KL, Zhao WQ, Ferreira ST, Klein WL. Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers. *Proc Natl Acad Sci USA.* 2009; 106(6): 1971–1976. doi:10.1073/pnas.0809158106. [PubMed: 19188609]
24. De Felice FG, Wasilewska-Sampaio AP, Barbosa AC, Gomes FC, Klein WL, Ferreira ST. Cyclic AMP enhancers and Abeta oligomerization blockers as potential therapeutic agents in Alzheimer's disease. *Curr Alzheimer Res.* 2007; 4(3):263–271. [PubMed: 17627483]
25. De Felice FG, Wu D, Lambert MP, Fernandez SJ, Velasco PT, Lacor PN, Bigio EH, Jerecic J, Acton PJ, Shughrue PJ, Chen-Dodson E, Kinney GG, Klein WL. Alzheimer's disease type neuronal tau hyperphosphorylation induced by A beta oligomers. *Neurobiol Aging.* 2008; 29(9): 1334–1347. doi:10.1016/j.neurobiolaging.2007.02.029. [PubMed: 17403556]
26. de la Monte SM. Type 3 diabetes is sporadic Alzheimer's disease: mini-review. *Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol.* 2014 doi:10.1016/j.euroneuro.2014.06.008.
27. de la Monte SM, Wands JR. Alzheimer's disease is type 3 diabetes-evidence reviewed. *J Diabetes Sci Technol.* 2008; 2(6):1101–1113. [PubMed: 19885299]
28. Di Scala C, Troadec JD, Lelievre C, Garmy N, Fantini J, Chahinian H. Mechanism of cholesterol-assisted oligomeric channel formation by a short Alzheimer beta-amyloid peptide. *J Neurochem.* 2014; 128(1):186–195. doi:10.1111/jnc.12390. [PubMed: 23919567]
29. Dodart JC, Bales KR, Gannon KS, Greene SJ, DeMattos RB, Mathis C, DeLong CA, Wu S, Wu X, Holtzman DM, Paul SM. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. *Nat Neurosci.* 2002; 5(5):452–457. doi:10.1038/nn842. [PubMed: 11941374]
30. Domert J, Rao SB, Agholme L, Brorsson AC, Marcusson J, Hallbeck M, Nath S. Spreading of amyloid-beta peptides via neuritic cell-to-cell transfer is dependent on insufficient cellular clearance. *Neurobiol Dis.* 2014; 65:82–92. doi:10.1016/j.nbd.2013.12.019. [PubMed: 24412310]
31. Dorostkar MM, Burgold S, Filser S, Barghorn S, Schmidt B, Anumala UR, Hillen H, Klein C, Herms J. Immunotherapy alleviates amyloid-associated synaptic pathology in an Alzheimer's disease mouse model. *Brain J Neurol.* 2014 doi:10.1093/brain/awu280.
32. Drolle E, Hane F, Lee B, Leonenko Z. Atomic force microscopy to study molecular mechanisms of amyloid fibril formation and toxicity in Alzheimer's disease. *Drug Metab Rev.* 2014; 46(2):207–223. doi:10.3109/03602532.2014.882354. [PubMed: 24495298]
33. Drzezga A, Lautenschlager N, Siebner H, Riemenschneider M, Willoch F, Minoshima S, Schwaiger M, Kurz A. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study. *Eur J Nucl Med Mol Imaging.* 2003; 30(8):1104–1113. doi:10.1007/s00259-003-1194-1. [PubMed: 12764551]
34. Duran-Gonzalez J, Michi ED, Elorza B, Perez-Cordova MG, Pacheco-Otalora LF, Touhami A, Paulson P, Perry G, Murray IV, Colom LV. Amyloid beta peptides modify the expression of antioxidant repair enzymes and a potassium channel in the septohippocampal system. *Neurobiol Aging.* 2013; 34(8):2071–2076. doi:10.1016/j.neurobiolaging.2013.02.005. [PubMed: 23473707]
35. Edison P, Archer HA, Hinz R, Hammers A, Pavese N, Tai YF, Hotton G, Cutler D, Fox N, Kennedy A, Rossor M, Brooks DJ. Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study. *Neurology.* 2007; 68(7):501–508. doi: 10.1212/01.wnl.0000244749.20056.d4. [PubMed: 17065593]
36. Esparza TJ, Zhao H, Cirrito JR, Cairns NJ, Bateman RJ, Holtzman DM, Brody DL. Amyloid-beta oligomerization in Alzheimer dementia versus high-pathology controls. *Ann Neurol.* 2013; 73(1): 104–119. doi:10.1002/ana.23748. [PubMed: 23225543]
37. Evangelisti E, Wright D, Zampagni M, Cascella R, Fiorillo C, Bagnoli S, Relini A, Nichino D, Scartabelli T, Nacmias B, Sorbi S, Cecchi C. Lipid rafts mediate amyloid-induced calcium dyshomeostasis and oxidative stress in Alzheimer's disease. *Curr Alzheimer Res.* 2013; 10(2): 143–153. [PubMed: 22950913]

38. Evangelisti E, Zampagni M, Cascella R, Becatti M, Fiorillo C, Caselli A, Bagnoli S, Nacmias B, Cecchi C. Plasma membrane injury depends on bilayer lipid composition in Alzheimer's disease. *J Alzheimer Dis.* 2014; 41(1):289–300. doi:10.3233/jad-131406.
39. Ferreira ST, Klein WL. The Abeta oligomer hypothesis for synapse failure and memory loss in Alzheimer's disease. *Neurobiol Learn Mem.* 2011; 96(4):529–543. doi:10.1016/j.nlm.2011.08.003. [PubMed: 21914486]
40. Ferretti MT, Bruno MA, Ducatenzeiler A, Klein WL, Cuello AC. Intracellular Abeta-oligomers and early inflammation in a model of Alzheimer's disease. *Neurobiol Aging.* 2012; 33(7):1329–1342. doi:10.1016/j.neurobiolaging.2011.01.007. [PubMed: 21414686]
41. Figueiredo CP, Clarke JR, Ledo JH, Ribeiro FC, Costa CV, Melo HM, Mota-Sales AP, Saraiva LM, Klein WL, Sebollela A, De Felice FG, Ferreira ST. Memantine rescues transient cognitive impairment caused by high-molecular-weight abeta oligomers but not the persistent impairment induced by lowmolecular-weight oligomers. *J Neurosci Off J Soc Neurosci.* 2013; 33(23):9626–9634. doi:10.1523/jneurosci.0482-13.2013.
42. Frackowiak J, Zoltowska A, Wisniewski HM. Non-fibrillar beta-amyloid protein is associated with smooth muscle cells of vessel walls in Alzheimer disease. *J Neuropathol Exp Neurol.* 1994; 53(6): 637–645. [PubMed: 7964904]
43. Gabbita SP, Srivastava MK, Eslami P, Johnson MF, Kobritz NK, Tweedie D, Greig NH, Zemlan FP, Sharma SP, Harris-White ME. Early intervention with a small molecule inhibitor for tumor necrosis factor-alpha prevents cognitive deficits in a triple transgenic mouse model of Alzheimer's disease. *J Neuroinflammation.* 2012; 9:99. doi:10.1186/1742-2094-9-99. [PubMed: 22632257]
44. Garai K, Frieden C. Quantitative analysis of the time course of Abeta oligomerization and subsequent growth steps using tetramethylrhodamine-labeled Abeta. *Proc Natl Acad Sci USA.* 2013; 110(9):3321–3326. doi:10.1073/pnas.1222478110. [PubMed: 23401512]
45. Georganopoulou DG, Chang L, Nam JM, Thaxton CS, Mufson EJ, Klein WL, Mirkin CA. Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease. *Proc Natl Acad Sci USA.* 2005; 102(7):2273–2276. doi:10.1073/pnas.0409336102. [PubMed: 15695586]
46. Gimenez-Llort L, Rivera-Hernandez G, Marin-Argany M, Sanchez-Quesada JL, Villegas S. Early intervention in the 3xTg-AD mice with an amyloid beta-antibody fragment ameliorates first hallmarks of Alzheimer disease. *mAbs.* 2013; 5(5):665–677. doi:10.4161/mabs.25424. [PubMed: 23884018]
47. Gong Y, Chang L, Viola KL, Lacor PN, Lambert MP, Finch CE, Krafft GA, Klein WL. Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. *Proc Natl Acad Sci USA.* 2003; 100(18):10417–10422. doi:10.1073/pnas.1834302100. [PubMed: 12925731]
48. Gouras GK, Tampellini D, Takahashi RH, Capetillo-Zarate E. Intraneuronal beta-amyloid accumulation and synapse pathology in Alzheimer's disease. *Acta Neuropathol.* 2010; 119(5): 523–541. doi:10.1007/s00401-010-0679-9. [PubMed: 20354705]
49. Goure WF, Krafft GA, Jerecic J, Hefti F. Targeting the proper amyloid-beta neuronal toxins: a path forward for Alzheimer's disease immunotherapeutics. *Alzheimers Res Ther.* 2014; 6(4):42. doi: 10.1186/alzrt272. [PubMed: 25045405]
50. Griffin WS. Perispinal etanercept: potential as an Alzheimer therapeutic. *J Neuroinflammation.* 2008; 5:3. doi:10.1186/1742-2094-5-3. [PubMed: 18186919]
51. Gruning CS, Klinker S, Wolff M, Schneider M, Toksoz K, Klein AN, Nagel-Steger L, Willbold D, Hoyer W. The off-rate of monomers dissociating from amyloid-beta protofibrils. *J Biol Chem.* 2013; 288(52):37104–37111. doi:10.1074/jbc.M113.513432. [PubMed: 24247242]
52. Gu L, Liu C, Guo Z. Structural insights into Abeta42 oligomers using site-directed spin labeling. *J Biol Chem.* 2013; 288(26):18673–18683. doi:10.1074/jbc.M113.457739. [PubMed: 23687299]
53. Guillot-Sestier MV, Sunyach C, Ferreira ST, Marzolo MP, Bauer C, Thevenet A, Checler F. Alpha-Secretase-derived fragment of cellular prion, N1, protects against monomeric and oligomeric amyloid beta (Abeta)-associated cell death. *J Biol Chem.* 2012; 287(7):5021–5032. doi: 10.1074/jbc.M111.323626. [PubMed: 22184125]

54. Guo JL, Covell DJ, Daniels JP, Iba M, Stieber A, Zhang B, Riddle DM, Kwong LK, Xu Y, Trojanowski JQ, Lee VM. Distinct alpha-synuclein strains differentially promote tau inclusions in neurons. *Cell*. 2013; 154(1):103–117. doi:10.1016/j.cell.2013.05.057. [PubMed: 23827677]
55. Guo JL, Lee VM. Seeding of normal Tau by pathological Tau conformers drives pathogenesis of Alzheimer-like tangles. *J Biol Chem*. 2011; 286(17):15317–15331. doi:10.1074/jbc.M110.209296. [PubMed: 21372138]
56. Haes AJ, Chang L, Klein WL, Van Duyne RP. Detection of a biomarker for Alzheimer's disease from synthetic and clinical samples using a nanoscale optical biosensor. *J Am Chem Soc*. 2005; 127(7):2264–2271. doi:10.1021/ja044087q. [PubMed: 15713105]
57. Han X, Ma Y, Liu X, Wang L, Qi S, Zhang Q, Du Y. Changes in insulin-signaling transduction pathway underlie learning/memory deficits in an Alzheimer's disease rat model. *J Neural Trans Vienna Austria* 1996. 2012; 119(11):1407–1416. doi:10.1007/s00702-012-0803-1.
58. Handoko M, Grant M, Kuskowski M, Zahs KR, Wallin A, Blennow K, Ashe KH. Correlation of specific amyloid-beta oligomers with tau in cerebrospinal fluid from cognitively normal older adults. *JAMA Neurol*. 2013; 70(5):594–599. doi:10.1001/jamaneurol.2013.48. [PubMed: 23479202]
59. Hauser PS, Ryan RO. Impact of apolipoprotein E on Alzheimer's disease. *Curr Alzheimer Res*. 2013; 10(8):809–817. [PubMed: 23919769]
60. Hayden EY, Teplow DB. Amyloid beta-protein oligomers and Alzheimer's disease. *Alzheimers Res Ther*. 2013; 5(6):60. doi:10.1186/alzrt226. [PubMed: 24289820]
61. Hefti F, Goure WF, Jerecic J, Iverson KS, Walicke PA, Krafft GA. The case for soluble Abeta oligomers as a drug target in Alzheimer's disease. *Trend Pharmacol Sci*. 2013; 34(5):261–266. doi:10.1016/j.tips.2013.03.002.
62. Heras-Sandoval D, Ferrera P, Arias C. Amyloid-beta protein modulates insulin signaling in presynaptic terminals. *Neurochem Res*. 2012; 37(9):1879–1885. doi:10.1007/s11064-012-0800-7. [PubMed: 22638775]
63. Holtta M, Hansson O, Andreasson U, Hertze J, Minthon L, Nagga K, Andreasen N, Zetterberg H, Blennow K. Evaluating amyloid-beta oligomers in cerebrospinal fluid as a biomarker for Alzheimer's disease. *PLoS One*. 2013; 8(6):e66381. doi:10.1371/journal.pone.0066381. [PubMed: 23799095]
64. Intlekofer KA, Cotman CW. Exercise counteracts declining hippocampal function in aging and Alzheimer's disease. *Neurobiol Dis*. 2013; 57:47–55. doi:10.1016/j.nbd.2012.06.011. [PubMed: 22750524]
65. Izuo N, Kume T, Sato M, Murakami K, Irie K, Izumi Y, Akaike A. Toxicity in rat primary neurons through the cellular oxidative stress induced by the turn formation at positions 22 and 23 of Abeta42. *ACS Chem Neurosci*. 2012; 3(9):674–681. doi:10.1021/cn300033k. [PubMed: 23019494]
66. Izzo NJ, Staniszewski A, To L, Fa M, Teich AF, Saeed F, Wostein H, Walko T 3rd, Vaswani A, Wardius M, Syed Z, Ravenscroft J, Mozzoni K, Silky C, Rehak C, Yurko R, Finn P, Look G, Rishton G, Safferstein H, Miller M, Johanson C, Stopa E, Windisch M, Hutter-Paier B, Shamloo M, Arancio O, LeVine H 3rd, Catalano SM. Alzheimer's therapeutics targeting amyloid Beta 1-42 oligomers I: abeta 42 oligomer binding to specific neuronal receptors is displaced by drug candidates that improve cognitive deficits. *PLoS One*. 2014; 9(11):e111898. doi:10.1371/journal.pone.0111898. [PubMed: 25390368]
67. Izzo NJ, Xu J, Zeng C, Kirk MJ, Mozzoni K, Silky C, Rehak C, Yurko R, Look G, Rishton G, Safferstein H, Cruchaga C, Goate A, Cahill MA, Arancio O, Mach RH, Craven R, Head E, LeVine H 3rd, Spires-Jones TL, Catalano SM. Alzheimer's therapeutics targeting amyloid beta 1-42 oligomers ii: sigma-2/pgrmc1 receptors mediate abeta 42 oligomer binding and synaptotoxicity. *PLoS One*. 2014; 9(11):e111899. doi:10.1371/journal.pone.0111899. [PubMed: 25390692]
68. Janelins MC, Mastrangelo MA, Park KM, Sudol KL, Narrow WC, Oddo S, LaFerla FM, Callahan LM, Federoff HJ, Bowers WJ. Chronic neuron-specific tumor necrosis factor alpha expression enhances the local inflammatory environment ultimately leading to neuronal death in 3xTg-AD mice. *Am J Pathol*. 2008; 173(6):1768–1782. doi:10.2353/ajpath.2008.080528. [PubMed: 18974297]

69. Jang H, Connelly L, Arce FT, Ramachandran S, Kagan BL, Lal R, Nussinov R. Mechanisms for the insertion of toxic, fibril-like beta-amyloid oligomers into the membrane. *J Chem Theory Comput.* 2013; 9(1):822–833. doi:10.1021/ct300916f. [PubMed: 23316126]
70. Jang H, Connelly L, Arce FT, Ramachandran S, Lal R, Kagan BL, Nussinov R. Alzheimer's disease: which type of amyloid-preventing drug agents to employ? *Phys Chem Chem Phys.* 2013; 15(23):8868–8877. doi:10.1039/c3cp00017f. [PubMed: 23450150]
71. Jeong JS, Ansaloni A, Mezzenga R, Lashuel HA, Dietler G. Novel mechanistic insight into the molecular basis of amyloid polymorphism and secondary nucleation during amyloid formation. *J Mol Biol.* 2013; 425(10):1765–1781. doi:10.1016/j.jmb.2013.02.005. [PubMed: 23415897]
72. Johnson RD, Steel DG, Gafni A. Structural evolution and membrane interactions of Alzheimer's amyloid-beta peptide oligomers: new knowledge from single-molecule fluorescence studies. *Protein Sci Publ Protein Soc.* 2014; 23(7):869–883. doi:10.1002/pro.2479.
73. Jonsson T, Atwal JK, Steinberg S, Snaedal J, Jonsson PV, Bjornsson S, Stefansson H, Sulem P, Gudbjartsson D, Maloney J, Hoyte K, Gustafson A, Liu Y, Lu Y, Bhangale T, Graham RR, Huttenlocher J, Bjornsdottir G, Andreassen OA, Jonsson EG, Palotie A, Behrens TW, Magnusson OT, Kong A, Thorsteinsdottir U, Watts RJ, Stefansson K. A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. *Nature.* 2012; 488(7409):96–99. doi: 10.1038/nature11283. [PubMed: 22801501]
74. Kalimo H, Lalowski M, Bogdanovic N, Philipson O, Bird TD, Nochlin D, Schellenberg GD, Brundin R, Olofsson T, Soliymani R, Baumann M, Wirths O, Bayer TA, Nilsson LN, Basun H, Lannfelt L, Ingelsson M. The Arctic AbetaPP mutation leads to Alzheimer's disease pathology with highly variable topographic deposition of differentially truncated Abeta. *Acta Neuropathol Commun.* 2013; 1(1):60. doi:10.1186/2051-5960-1-60. [PubMed: 24252272]
75. Kaye R, Head E, Sarsoza F, Saing T, Cotman CW, Necula M, Margol L, Wu J, Breydo L, Thompson JL, Rasool S, Gurlo T, Butler P, Glabe CG. Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. *Mol Neurodegener.* 2007; 2:18. doi:10.1186/1750-1326-2-18. [PubMed: 17897471]
76. Kaye R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, Glabe CG. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. *Science NY.* 2003; 300(5618):486–489. doi:10.1126/science.1079469.
77. Kaye R, Lasagna-Reeves CA. Molecular mechanisms of amyloid oligomers toxicity. *J Alzheimer Dis.* 2013; 33(Suppl 1):S67–S78. doi:10.3233/jad-2012-129001.
78. Kerchner GA, Boxer AL. Bapineuzumab. *Expert Opin Biol Ther.* 2010; 10(7):1121–1130. doi: 10.1517/14712598.2010.493872. [PubMed: 20497044]
79. Kim HG, Moon M, Choi JG, Park G, Kim AJ, Hur J, Lee KT, Oh MS. Donepezil inhibits the amyloid-beta oligomer-induced microglial activation in vitro and in vivo. *Neurotoxicology.* 2014; 40:23–32. doi:10.1016/j.neuro.2013.10.004. [PubMed: 24189446]
80. Kim HJ, Chae SC, Lee DK, Chromy B, Lee SC, Park YC, Klein WL, Krafft GA, Hong ST. Selective neuronal degeneration induced by soluble oligomeric amyloid beta protein. *FASEB J Off Publ Fed Am Soc Exp Biol.* 2003; 17(1):118–120. doi:10.1096/fj.01-0987fje.
81. Klein WL. Synaptotoxic amyloid-beta oligomers: a molecular basis for the cause, diagnosis, and treatment of Alzheimer's disease? *J Alzheimer Dis.* 2013; 33(Suppl 1):S49–S65. doi:10.3233/jad-2012-129039.
82. Klein WL, Krafft GA, Finch CE. Targeting small Abeta oligomers: the solution to an Alzheimer's disease conundrum? *Trends Neurosci.* 2001; 24(4):219–224. [PubMed: 11250006]
83. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergstrom M, Savitcheva I, Huang GF, Estrada S, Ausen B, Debnath ML, Barletta J, Price JC, Sandell J, Lopresti BJ, Wall A, Koivisto P, Antoni G, Mathis CA, Langstrom B. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. *Ann Neurol.* 2004; 55(3):306–319. doi:10.1002/ana.20009. [PubMed: 14991808]
84. Klyubin I, Cullen WK, Hu NW, Rowan MJ. Alzheimer's disease Abeta assemblies mediating rapid disruption of synaptic plasticity and memory. *Mol Brain.* 2012; 5:25. doi: 10.1186/1756-6606-5-25. [PubMed: 22805374]

85. Kodali R, Wetzel R. Polymorphism in the intermediates and products of amyloid assembly. *Curr Opin Struct Biol.* 2007; 17(1):48–57. doi:10.1016/j.sbi.2007.01.007. [PubMed: 17251001]
86. Koffie RM, Hyman BT, Spires-Jones TL. Alzheimer's disease: synapses gone cold. *Mol Neurodegener.* 2011; 6(1):63. doi:10.1186/1750-1326-6-63. [PubMed: 21871088]
87. Koffie RM, Meyer-Luehmann M, Hashimoto T, Adams KW, Mielke ML, Garcia-Alloza M, Micheva KD, Smith SJ, Kim ML, Lee VM, Hyman BT, Spires-Jones TL. Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. *Proc Natl Acad Sci USA.* 2009; 106(10):4012–4017. doi:10.1073/pnas.0811698106. [PubMed: 19228947]
88. Kovacs GG, Breydo L, Green R, Kis V, Puska G, Lorincz P, Perju-Dumbrava L, Giera R, Pirker W, Lutz M, Lachmann I, Budka H, Uversky VN, Molnar K, Laszlo L. Intracellular processing of disease-associated alpha-synuclein in the human brain suggests prion-like cell-to-cell spread. *Neurobiol Dis.* 2014; 69:76–92. doi:10.1016/j.nbd.2014.05.020. [PubMed: 24878508]
89. Kumar A, Paslay LC, Lyons D, Morgan SE, Correia JJ, Rangachari V. Specific soluble oligomers of amyloid-beta peptide undergo replication and form non-fibrillar aggregates in interfacial environments. *J Biol Chem.* 2012; 287(25):21253–21264. doi:10.1074/jbc.M112.355156. [PubMed: 22544746]
90. Kuszczak MA, Sanchez S, Pankiewicz J, Kim J, Duszczak M, Guridi M, Asuni AA, Sullivan PM, Holtzman DM, Sadowski MJ. Blocking the interaction between apolipoprotein E and Abeta reduces intraneuronal accumulation of Abeta and inhibits synaptic degeneration. *Am J Pathol.* 2013; 182(5):1750–1768. doi:10.1016/j.ajpath.2013.01.034. [PubMed: 23499462]
91. Lacor PN, Buniel MC, Chang L, Fernandez SJ, Gong Y, Viola KL, Lambert MP, Velasco PT, Bigio EH, Finch CE, Krafft GA, Klein WL. Synaptic targeting by Alzheimer's-related amyloid beta oligomers. *J Neurosci Off J Soc Neurosci.* 2004; 24(45):10191–10200. doi:10.1523/jneurosci.3432-04.2004.
92. Lacor PN, Buniel MC, Furlow PW, Clemente AS, Velasco PT, Wood M, Viola KL, Klein WL. Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. *J Neurosci Off J Soc Neurosci.* 2007; 27(4):796–807. doi:10.1523/jneurosci.3501-06.2007.
93. Ladiwala AR, Litt J, Kane RS, Aucoin DS, Smith SO, Ranjan S, Davis J, Van Nostrand WE, Tessier PM. Conformational differences between two amyloid beta oligomers of similar size and dissimilar toxicity. *J Biol Chem.* 2012; 287(29):24765–24773. doi:10.1074/jbc.M111.329763. [PubMed: 22547072]
94. Laganowsky A, Liu C, Sawaya MR, Whitelegge JP, Park J, Zhao M, Pensalfini A, Soriaga AB, Landau M, Teng PK, Cascio D, Glabe C, Eisenberg D. Atomic view of a toxic amyloid small oligomer. *Sci NY.* 2012; 335(6073):1228–1231. doi:10.1126/science.1213151.
95. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL, Wals P, Zhang C, Finch CE, Krafft GA, Klein WL. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. *Proc Natl Acad Sci USA.* 1998; 95(11):6448–6453. [PubMed: 9600986]
96. Lambert MP, Velasco PT, Chang L, Viola KL, Fernandez S, Lacor PN, Khuon D, Gong Y, Bigio EH, Shaw P, De Felice FG, Krafft GA, Klein WL. Monoclonal antibodies that target pathological assemblies of Abeta. *J Neurochem.* 2007; 100(1):23–35. doi:10.1111/j.1471-4159.2006.04157.x. [PubMed: 17116235]
97. Lambert MP, Viola KL, Chromy BA, Chang L, Morgan TE, Yu J, Venton DL, Krafft GA, Finch CE, Klein WL. Vaccination with soluble Abeta oligomers generates toxicity-neutralizing antibodies. *J Neurochem.* 2001; 79(3):595–605. [PubMed: 11701763]
98. Lannfelt L, Moller C, Basun H, Osswald G, Sehlin D, Satlin A, Logovinsky V, Gellerfors P. Perspectives on future Alzheimer therapies: amyloid-beta protofibrils—a new target for immunotherapy with BAN2401 in Alzheimer's disease. *Alzheimers Res Ther.* 2014; 6(2):16. doi:10.1186/alzrt246. [PubMed: 25031633]
99. Lasagna-Reeves CA, Glabe CG, Kaye R. Amyloid-beta annular protofibrils evade fibrillar fate in Alzheimer disease brain. *J Biol Chem.* 2011; 286(25):22122–22130. doi:10.1074/jbc.M111.236257. [PubMed: 21507938]

100. Lauren J. Cellular prion protein as a therapeutic target in Alzheimer's disease. *J Alzheimer Dis.* 2014; 38(2):227–244. doi:10.3233/jad-130950.
101. Lauren J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. *Nature.* 2009; 457(7233):1128–1132. doi:10.1038/nature07761. [PubMed: 19242475]
102. Lee EB, Leng LZ, Zhang B, Kwong L, Trojanowski JQ, Abel T, Lee VM. Targeting amyloid-beta peptide (Abeta) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Abeta precursor protein (APP) transgenic mice. *J Biol Chem.* 2006; 281(7):4292–4299. doi:10.1074/jbc.M511018200. [PubMed: 16361260]
103. Lee M, Guo JP, Schwab C, McGeer EG, McGeer PL. Selective inhibition of the membrane attack complex of complement by low molecular weight components of the aurin tricarboxylic acid synthetic complex. *Neurobiol Aging.* 2012; 33(10):2237–2246. doi:10.1016/j.neurobiolaging.2011.12.005. [PubMed: 22217416]
104. Lee SH, Kim Y, Kim HY, Kim YH, Kim MS, Kong JY, Lee MH, Kim DJ, Ahn YG. Aminostyrylbenzofuran directly reduces oligomeric amyloid-beta and reverses cognitive deficits in Alzheimer transgenic mice. *PLoS One.* 2014; 9(4):e95733. doi:10.1371/journal.pone.0095733. [PubMed: 24760018]
105. Lesne S, Koh MT, Kotilinek L, Kaye R, Glabe CG, Yang A, Gallagher M, Ashe KH. A specific amyloid-beta protein assembly in the brain impairs memory. *Nature.* 2006; 440(7082):352–357. doi:10.1038/nature04533. [PubMed: 16541076]
106. LeVine H 3rd. Alzheimer's beta-peptide oligomer formation at physiologic concentrations. *Anal Biochem.* 2004; 335(1):81–90. doi:10.1016/j.ab.2004.08.014. [PubMed: 15519574]
107. Li S, Jin M, Zhang D, Yang T, Koeglsperger T, Fu H, Selkoe DJ. Environmental novelty activates beta2-adrenergic signaling to prevent the impairment of hippocampal LTP by Abeta oligomers. *Neuron.* 2013; 77(5):929–941. doi:10.1016/j.neuron.2012.12.040. [PubMed: 23473322]
108. Liu-Seifert H, Siemers E, Sundell K, Price K, Han B, Selzler K, Aisen P, Cummings J, Raskin J, Mohs R. Cognitive and functional decline and their relationship in patients with mild Alzheimer's dementia. *J Alzheimer Dis.* 2014 doi:10.3233/jad-140792.
109. Liu C, Zhao M, Jiang L, Cheng PN, Park J, Sawaya MR, Pensalfini A, Gou D, Berk AJ, Glabe CG, Nowick J, Eisenberg D. Out-of-register beta-sheets suggest a pathway to toxic amyloid aggregates. *Proc Natl Acad Sci USA.* 2012; 109(51):20913–20918. doi:10.1073/pnas.1218792109. [PubMed: 23213214]
110. Lorenzen N, Nielsen SB, Buell AK, Kaspersen JD, Arosio P, Vad BS, Paslawski W, Christiansen G, Valnickova-Hansen Z, Andreasen M, Enghild JJ, Pedersen JS, Dobson CM, Knowles TP, Otzen DE. The role of stable alpha-synuclein oligomers in the molecular events underlying amyloid formation. *J Am Chem Soc.* 2014; 136(10):3859–3868. doi:10.1021/ja411577t. [PubMed: 24527756]
111. Lourenco MV, Clarke JR, Frozza RL, Bomfim TR, Forny-Germano L, Batista AF, Sathler LB, Brito-Moreira J, Amaral OB, Silva CA, Freitas-Correa L, Espirito-Santo S, Campello-Costa P, Houzel JC, Klein WL, Holscher C, Carvalheira JB, Silva AM, Velloso LA, Munoz DP, Ferreira ST, De Felice FG. TNF-alpha mediates PKR-dependent memory impairment and brain IRS-1 inhibition induced by Alzheimer's beta-amyloid oligomers in mice and monkeys. *Cell Metab.* 2013; 18(6):831–843. doi:10.1016/j.cmet.2013.11.002. [PubMed: 24315369]
112. Maesako M, Uemura K, Iwata A, Kubota M, Watanabe K, Uemura M, Noda Y, Asada-Utsugi M, Kihara T, Takahashi R, Shimohama S, Kinoshita A. Continuation of exercise is necessary to inhibit high fat diet-induced beta-amyloid deposition and memory deficit in amyloid precursor protein transgenic mice. *PLoS One.* 2013; 8(9):e72796. doi:10.1371/journal.pone.0072796. [PubMed: 24023774]
113. Magnusson K, Sehlin D, Syvanen S, Svedberg MM, Philipson O, Soderberg L, Tegerstedt K, Holmquist M, Gellerfors P, Tolmachev V, Antoni G, Lannfelt L, Hall H, Nilsson LN. Specific uptake of an amyloid-beta protofibril-binding antibody-tracer in AbetaPP transgenic mouse brain. *J Alzheimer Dis.* 2013; 37(1):29–40. doi:10.3233/jad-130029.

114. Mainardi M, Di Garbo A, Caleo M, Berardi N, Sale A, Maffei L. Environmental enrichment strengthens corticocortical interactions and reduces amyloid-beta oligomers in aged mice. *Front Aging Neurosci.* 2014; 6:1. doi:10.3389/fnagi.2014.00001. [PubMed: 24478697]
115. Matsubara E, Takamura A, Okamoto Y, Oono H, Nakata T, Wakasaya Y, Kawarabayashi T, Shoji M. Disease modifying therapies for Alzheimer's disease targeting Abeta oligomers: implications for therapeutic mechanisms. *Biomed Resh Int.* 2013; 2013:984041. doi: 10.1155/2013/984041.
116. McAlpine FE, Lee JK, Harms AS, Ruhn KA, Blurton-Jones M, Hong J, Das P, Golde TE, LaFerla FM, Oddo S, Blesch A, Tansey MG. Inhibition of soluble TNF signaling in a mouse model of Alzheimer's disease prevents pre-plaque amyloid-associated neuropathology. *Neurobiol Dis.* 2009; 34(1):163–177. [PubMed: 19320056]
117. McClean PL, Holscher C. Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease. *Neuropharmacology.* 2014; 76:57–67. Pt A. doi:10.1016/j.neuropharm.2013.08.005. [PubMed: 23973293]
118. McLean D, Cooke MJ, Wang Y, Green D, Fraser PE, George-Hyslop PS, Shoichet MS. Anti-amyloid-beta-mediated positron emission tomography imaging in Alzheimer's disease mouse brains. *PLoS One.* 2012; 7(12):e51958. doi:10.1371/journal.pone.0051958. [PubMed: 23284831]
119. Moon M, Kim HG, Choi JG, Oh H, Lee PK, Ha SK, Kim SY, Park Y, Huh Y, Oh MS. 6-Shogaol, an active constituent of ginger, attenuates neuroinflammation and cognitive deficits in animal models of dementia. *Biochem Biophys Res Commun.* 2014; 449(1):8–13. doi:10.1016/j.bbrc.2014.04.121. [PubMed: 24796668]
120. Morkuniene R, Zvirbliene A, Dalgediene I, Cizas P, Jankeviciute S, Baliutyte G, Jokubka R, Jankunec M, Valincius G, Borutaite V. Antibodies bound to Abeta oligomers potentiate the neurotoxicity of Abeta by activating microglia. *J Neurochem.* 2013; 126(5):604–615. doi: 10.1111/jnc.12332. [PubMed: 23745639]
121. Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein EM, Tatsuno G, Hu K, Kholodenko D, Johnson-Wood K, McConlogue L. High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. *J Neurosci.* 2000; 20(11):4050–4058. [PubMed: 10818140]
122. Mucke L, Selkoe DJ. Neurotoxicity of amyloid betaprotein: synaptic and network dysfunction. *Cold Spring Harb Perspect Med.* 2012; 2(7):a006338. doi:10.1101/cshperspect.a006338. [PubMed: 22762015]
123. Mufson EJ, Ward S, Binder L. Prefibrillar tau oligomers in mild cognitive impairment and Alzheimer's disease. *Neurodegener Dis.* 2014; 13(2–3):151–153. doi:10.1159/000353687. [PubMed: 24029627]
124. Murakami K. Conformation-specific antibodies to target amyloid beta oligomers and their application to immunotherapy for Alzheimer's disease. *Biosci Biotechnol Biochem.* 2014; 78(8): 1293–1305. doi:10.1080/09168451.2014.940275. [PubMed: 25130729]
125. Narayan P, Ganzinger KA, McColl J, Weimann L, Meehan S, Qamar S, Carver JA, Wilson MR, St George-Hyslop P, Dobson CM, Klenerman D. Single molecule characterization of the interactions between amyloid-beta peptides and the membranes of hippocampal cells. *J Am Chem Soc.* 2013; 135(4):1491–1498. doi:10.1021/ja3103567. [PubMed: 23339742]
126. Narayan P, Holmstrom KM, Kim DH, Whitcomb DJ, Wilson MR, St George-Hyslop P, Wood NW, Dobson CM, Cho K, Abramov AY, Klenerman D. Rare individual amyloid-beta oligomers act on astrocytes to initiate neuronal damage. *Biochemistry.* 2014; 53(15):2442–2453. doi: 10.1021/bi401606f. [PubMed: 24717093]
127. Nath S, Agholme L, Kurudenkandy FR, Granseth B, Marcusson J, Hallbeck M. Spreading of neurodegenerative pathology via neuron-to-neuron transmission of beta-amyloid. *J Neurosci Off J Soc Neurosci.* 2012; 32(26):8767–8777. doi:10.1523/jneurosci.0615-12.2012.
128. Nigh AB, Vahedi S, Davis EG, Weintraub S, Bigio EH, Klein WL, Geula C. Intracellular Amyloid-beta in cholinergic neurons. *Brain J Neurol.* 2014 In Press.
129. Nussbaum JM, Schilling S, Cynis H, Silva A, Swanson E, Wangsanut T, Tayler K, Wiltgen B, Hatami A, Ronicke R, Reymann K, Hutter-Paier B, Alexandru A, Jagla W, Graubner S, Glabe CG, Demuth HU, Bloom GS. Prion-like behaviour and tau-dependent cytotoxicity of

- pyroglutamylated amyloidbeta. *Nature*. 2012; 485(7400):651–655. doi:10.1038/nature11060. [PubMed: 22660329]
130. Nyborg AC, Moll JR, Wegrzyn RD, Havas D, Hutter-Paier B, Feuerstein GG, Rudolph AS. In vivo and ex vivo imaging of amyloid-beta cascade aggregates with a Pronucleon peptide. *J Alzheimer Dis*. 2013; 34(4):957–967. doi:10.3233/jad-122107.
 131. Oda T, Pasinetti GM, Osterburg HH, Anderson C, Johnson SA, Finch CE. Purification and characterization of brain clusterin. *Biochem Biophys Res Commun*. 1994; 204(3):1131–1136. doi:10.1006/bbrc.1994.2580. [PubMed: 7980587]
 132. Oddo S, Caccamo A, Tran L, Lambert MP, Glabe CG, Klein WL, LaFerla FM. Temporal profile of amyloid-beta (A β) oligomerization in an in vivo model of Alzheimer disease. A link between A β and tau pathology. *J Biol Chem*. 2006; 281(3):1599–1604. doi:10.1074/jbc.M507892200.
 133. Olanow CW, Brundin P. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder? *Mov Disord Off J Mov Disorder Soc*. 2013; 28(1):31–40. doi:10.1002/mds.25373.
 134. Ono K, Takahashi R, Ikeda T, Yamada M. Cross-seeding effects of amyloid beta-protein and alpha-synuclein. *J Neurochem*. 2012; 122(5):883–890. doi:10.1111/j.1471-4159.2012.07847.x. [PubMed: 22734715]
 135. Pearson-Leary J, McNay EC. Intrahippocampal administration of amyloid-beta(1-42) oligomers acutely impairs spatial working memory, insulin signaling, and hippocampal metabolism. *J Alzheimer Dis*. 2012; 30(2):413–422. doi:10.3233/jad-2012-112192.
 136. Peng S, Garzon DJ, Marchese M, Klein W, Ginsberg SD, Francis BM, Mount HT, Mufson EJ, Salehi A, Fahnstock M. Decreased brain-derived neurotrophic factor depends on amyloid aggregation state in transgenic mouse models of Alzheimer's disease. *J Neurosci Off J Soc Neurosci*. 2009; 29(29):9321–9329. doi:10.1523/JNEUROSCI.4736-08.2009.
 137. Peters C, Fernandez-Perez EJ, Burgos CF, Espinoza MP, Castillo C, Urrutia JC, Streltsov VA, Opazo C, Aguayo LG. Inhibition of amyloid beta-induced synaptotoxicity by a pentapeptide derived from the glycine zipper region of the neurotoxic peptide. *Neurobiol Aging*. 2013; 34(12):2805–2814. doi:10.1016/j.neurobiolaging.2013.06.001. [PubMed: 23855983]
 138. Pitt J, Roth W, Lacor P, Smith AB 3rd, Blankenship M, Velasco P, De Felice F, Breslin P, Klein WL. Alzheimer's-associated A β oligomers show altered structure, immunoreactivity and synaptotoxicity with low doses of oleocanthal. *Toxicol Appl Pharmacol*. 2009; 240(2):189–197. doi:10.1016/j.taap.2009.07.018. [PubMed: 19631677]
 139. Pozueta J, Lefort R, Shelanski ML. Synaptic changes in Alzheimer's disease and its models. *Neuroscience*. 2013; 251:51–65. doi:10.1016/j.neuroscience.2012.05.050. [PubMed: 22687952]
 140. Prangkio P, Yusko EC, Sept D, Yang J, Mayer M. Multivariate analyses of amyloid-beta oligomer populations indicate a connection between pore formation and cytotoxicity. *PLoS One*. 2012; 7(10):e47261. doi:10.1371/journal.pone.0047261. [PubMed: 23077580]
 141. Purro SA, Dickins EM, Salinas PC. The secreted Wnt antagonist Dickkopf-1 is required for amyloid beta-mediated synaptic loss. *J Neurosci Off J Soc Neurosci*. 2012; 32(10):3492–3498. doi:10.1523/jneurosci.4562-11.2012.
 142. Rasool S, Martinez-Coria H, Wu JW, LaFerla F, Glabe CG. Systemic vaccination with anti-oligomeric monoclonal antibodies improves cognitive function by reducing A β deposition and tau pathology in 3xTg-AD mice. *J Neurochem*. 2013; 126(4):473–482. doi:10.1111/jnc.12305. [PubMed: 23672786]
 143. Renner M, Lacor PN, Velasco PT, Xu J, Contractor A, Klein WL, Triller A. Deleterious effects of amyloid beta oligomers acting as an extracellular scaffold for mGluR5. *Neuron*. 2010; 66(5):739–754. doi:10.1016/j.neuron.2010.04.029. [PubMed: 20547131]
 144. Resende R, Marques SC, Ferreiro E, Simoes I, Oliveira CR, Pereira CM. Effect of alpha-synuclein on amyloid beta-induced toxicity: relevance to Lewy body variant of Alzheimer disease. *Neurochem Res*. 2013; 38(4):797–806. doi:10.1007/s11064-013-0982-7. [PubMed: 23389658]
 145. Richman M, Wilk S, Chemerovski M, Warmlander SK, Wahlstrom A, Graslund A, Rahimpour S. In vitro and mechanistic studies of an anti-amyloidogenic self-assembled cyclic D, L-alpha-

- peptide architecture. *J Am Chem Soc.* 2013; 135(9):3474–3484. doi:10.1021/ja310064v. [PubMed: 23360549]
146. Ringman JM, Tomic JL, Coppola G, Elashoff D, Gylys KH, Glabe CG. Conformation-dependent oligomers in cerebrospinal fluid of presymptomatic familial Alzheimer's disease mutation carriers. *Dement Geriatr Cognit Disord Extra.* 2012; 2(1):652–657. doi:10.1159/000345771.
 147. Robinson R. MRI probe for amyloid-beta oligomers offers potential advantages for detecting Alzheimer's disease. *Neurol Today.* 2012; 12(24):20–22. doi:10.1097/01.NT.0000425719.88852.88.
 148. Rosenblum WI. Why Alzheimer trials fail: removing soluble oligomeric beta amyloid is essential, inconsistent, and difficult. *Neurobiol Aging.* 2014; 35(5):969–974. doi:10.1016/j.neurobiolaging.2013.10.085. [PubMed: 24210593]
 149. Roychaudhuri R, Lomakin A, Bernstein S, Zheng X, Condron MM, Benedek GB, Bowers M, Teplow DB. Gly25-Ser26 amyloid beta-protein structural isomorphs produce distinct Abeta42 conformational dynamics and assembly characteristics. *J Mol Biol.* 2014; 426(13):2422–2441. doi:10.1016/j.jmb.2014.04.004. [PubMed: 24735871]
 150. Roychaudhuri R, Yang M, Deshpande A, Cole GM, Frautschy S, Lomakin A, Benedek GB, Teplow DB. C-terminal turn stability determines assembly differences between Abeta40 and Abeta42. *J Mol Biol.* 2013; 425(2):292–308. doi:10.1016/j.jmb.2012.11.006. [PubMed: 23154165]
 151. Santucci A, Sytnyk V, Leshchynska I, Schachner M. Prion protein recruits its neuronal receptor NCAM to lipid rafts to activate p59fyn and to enhance neurite outgrowth. *J Cell Biol.* 2005; 169(2):341–354. doi:10.1083/jcb.200409127. [PubMed: 15851519]
 152. Sarkar B, Das AK, Maiti S. Thermodynamically stable amyloid-beta monomers have much lower membrane affinity than the small oligomers. *Front Physiol.* 2013; 4:84. doi:10.3389/fphys.2013.00084. [PubMed: 23781202]
 153. Sarkar B, Mithu VS, Chandra B, Mandal A, Chandrasekaran M, Bhowmik D, Madhu PK, Maiti S. Significant structural differences between transient amyloid-beta oligomers and less-toxic fibrils in regions known to harbor familial Alzheimer's mutations. *Angew Chem Int Ed Engl.* 2014; 53(27):6888–6892. doi:10.1002/anie.201402636. [PubMed: 24756858]
 154. Schmidt V, Carlo AS, Willnow TE. Apolipoprotein E receptor pathways in Alzheimer disease. *Wiley interdisciplinary reviews Systems biology and medicine.* 2014; 6(3):255–270. doi:10.1002/wsbm.1262. [PubMed: 24604742]
 155. Schnabel J. Amyloid: little proteins, big clues. *Nature.* 2011; 475(7355):S12–S14. doi:10.1038/475S12a. [PubMed: 21760575]
 156. Sebollela A, Freitas-Correa L, Oliveira FF, Mendes CT, Wasilewska-Sampaio AP, Camacho-Pereira J, Galina A, Brentani H, Passetti F, De Felice FG, Dias-Neto E, Ferreira ST. Expression profile of rat hippocampal neurons treated with the neuroprotective compound 2,4-dinitrophenol: up-regulation of cAMP signaling genes. *Neurotox Res.* 2010; 18(2):112–123. doi:10.1007/s12640-009-9133-y. [PubMed: 19949915]
 157. Selkoe DJ. Resolving controversies on the path to Alzheimer's therapeutics. *Nat Med.* 2011; 17(9):1060–1065. doi:10.1038/nm.2460. [PubMed: 21900936]
 158. Siemers ER, Friedrich S, Dean RA, Gonzales CR, Farlow MR, Paul SM, Demattos RB. Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease. *Clin Neuropharmacol.* 2010; 33(2):67–73. doi:10.1097/WNF.0b013e3181cb577a. [PubMed: 20375655]
 159. Sitkiewicz E, Kloniecki M, Poznanski J, Bal W, Dadlez M. Factors influencing compact-extended structure equilibrium in oligomers of abeta1-40 peptide—an ion mobility mass spectrometry study. *J Mol Biol.* 2014; 426(15):2871–2885. doi:10.1016/j.jmb.2014.05.015. [PubMed: 24857861]
 160. Soejima N, Ohyagi Y, Nakamura N, Himeno E, Iinuma KM, Sakae N, Yamasaki R, Tabira T, Murakami K, Irie K, Kinoshita N, LaFerla FM, Kiyohara Y, Iwaki T, Kira J. Intracellular accumulation of toxic turn amyloid-beta is associated with endoplasmic reticulum stress in Alzheimer's disease. *Curr Alzheimer Res.* 2013; 10(1):11–20. [PubMed: 22950910]

161. Sorgjerd KM, Zako T, Sakono M, Stirling PC, Leroux MR, Saito T, Nilsson P, Sekimoto M, Saido TC, Maeda M. Human prefoldin inhibits amyloid-beta (Abeta) fibrillation and contributes to formation of nontoxic Abeta aggregates. *Bio-chemistry*. 2013; 52(20):3532–3542. doi: 10.1021/bi301705c.
162. Takahashi RH, Capetillo-Zarate E, Lin MT, Milner TA, Gouras GK. Accumulation of intraneuronal beta-amyloid 42 peptides is associated with early changes in microtubule-associated protein 2 in neurites and synapses. *PLoS ONE*. 2013; 8(1):e51965. doi:10.1371/journal.pone.0051965. [PubMed: 23372648]
163. Takamura A, Sato Y, Watabe D, Okamoto Y, Nakata T, Kawarabayashi T, Oddo S, Laferla FM, Shoji M, Matsubara E. Sortilin is required for toxic action of Abeta oligomers (AbetaOs): extracellular AbetaOs trigger apoptosis, and intraneuronal AbetaOs impair degradation pathways. *Life Sci*. 2012; 91(23–24):1177–1186. doi:10.1016/j.lfs.2012.04.038. [PubMed: 22579764]
164. Takeda S, Hashimoto T, Roe AD, Hori Y, Spires-Jones TL, Hyman BT. Brain interstitial oligomeric amyloid beta increases with age and is resistant to clearance from brain in a mouse model of Alzheimer's disease. *FASEB J Off Publ Fed Am Soc Exp Biol*. 2013; 27(8):3239–3248. doi:10.1096/fj.13-229666.
165. Tay WM, Huang D, Rosenberry TL, Paravastu AK. The Alzheimer's amyloid-beta(1-42) peptide forms off-pathway oligomers and fibrils that are distinguished structurally by intermolecular organization. *J Mol Biol*. 2013; 425(14):2494–2508. doi:10.1016/j.jmb.2013.04.003. [PubMed: 23583777]
166. Thapa A, Vernon BC, De la Pena K, Soliz G, Moreno HA, Lopez GP, Chi EY. Membrane-mediated neuroprotection by curcumin from amyloid-beta-peptide-induced toxicity. *Langmuir : the ACS journal of surfaces and colloids*. 2013; 29(37):11713–11723. doi:10.1021/la4020459. [PubMed: 24004419]
167. Torok B, Sood A, Bag S, Kulkarni A, Borkin D, Lawler E, Dasgupta S, Landge S, Abid M, Zhou W, Foster M, LeVine H 3rd, Torok M. Structure-activity relationships of organofluorine inhibitors of beta-amyloid self-assembly. *Chem Med Chem*. 2012; 7(5):910–919. doi:10.1002/cmdc.201100569. [PubMed: 22351619]
168. Tsigelny IF, Sharikov Y, Kouznetsova VL, Greenberg JP, Wrasidlo W, Gonzalez T, Desplats P, Michael SE, Trejo-Morales M, Overk CR, Masliah E. Structural diversity of Alzheimer's disease amyloid-beta dimers and their role in oligomerization and fibril formation. *J Alzheimer Dis*. 2014; 39(3):583–600. doi:10.3233/jad-131589.
169. Tucker S, Moller C, Tegerstedt K, Lord A, Laudon H, Sjodahl J, Soderberg L, Spens E, Sahlin C, Waara ER, Satlin A, Gellerfors P, Osswald G, Lannfelt L. The murine version of BAN2401 (mAb158) selectively reduces amyloid-beta protofibrils in brain and cerebrospinal fluid of tg-arcsw mice. *J Alzheimer Dis*. 2014 doi:10.3233/jad-140741.
170. Um JW, Strittmatter SM. Amyloid-beta induced signaling by cellular prion protein and Fyn kinase in Alzheimer disease. *Prion*. 2013; 7(1):37–41. doi:10.4161/pri.22212. [PubMed: 22987042]
171. Um JW, Kaufman AC, Kostylev M, Heiss JK, Stagi M, Takahashi H, Kerrisk ME, Vortmeyer A, Wisniewski T, Koleske AJ, Gunther EC, Nygaard HB, Strittmatter SM. Metabotropic glutamate receptor 5 is a coreceptor for Alzheimer abeta oligomer bound to cellular prion protein. *Neuron*. 2013; 79(5):887–902. doi:10.1016/j.neuron.2013.06.036. [PubMed: 24012003]
172. Umeda T, Tomiyama T, Kitajima E, Idomoto T, Nomura S, Lambert MP, Klein WL, Mori H. Hypercholesterolemia accelerates intraneuronal accumulation of Abeta oligomers resulting in memory impairment in Alzheimer's disease model mice. *Life Sci*. 2012; 91(23–24):1169–1176. doi:10.1016/j.lfs.2011.12.022. [PubMed: 22273754]
173. Velasco PT, Heffern MC, Sebollela A, Popova IA, Lacor PN, Lee KB, Sun X, Tiano BN, Viola KL, Eckermann AL, Meade TJ, Klein WL. Synapse-binding subpopulations of Abeta oligomers sensitive to peptide assembly blockers and scFv antibodies. *ACS Chem Neurosci*. 2012; 3(11):972–981. doi:10.1021/cn300122k. [PubMed: 23173076]
174. Viola KL, Sbarboro J, Sureka R, De M, Bicca MA, Wang J, Vasavada S, Satpathy S, Wu S, Joshi H, Velasco PT, MacRenaris K, Waters EA, Lu C, Phan J, Lacor P, Prasad P, Dravid VP, Klein WL. Towards non-invasive diagnostic imaging of early-stage Alzheimer's disease. *Nat Nanotechnol*. 2014 doi:10.1038/nnano.2014.254.

175. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. *Nature*. 2002; 416(6880):535–539. doi:10.1038/416535a. [PubMed: 11932745]
176. Walsh DM, Tseng BP, Rydel RE, Podlisny MB, Selkoe DJ. The oligomerization of amyloid beta-protein begins intracellularly in cells derived from human brain. *Biochemistry*. 2000; 39(35): 10831–10839. [PubMed: 10978169]
177. Wang HW, Pasternak JF, Kuo H, Ristic H, Lambert MP, Chromy B, Viola KL, Klein WL, Stine WB, Krafft GA, Trommer BL. Soluble oligomers of beta amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. *Brain Res*. 2002; 924(2):133–140. [PubMed: 11750898]
178. Wang XP, Zhang JH, Wang YJ, Feng Y, Zhang X, Sun XX, Li JL, Du XT, Lambert MP, Yang SG, Zhao M, Klein WL, Liu RT. Conformation-dependent single-chain variable fragment antibodies specifically recognize beta-amyloid oligomers. *FEBS Lett*. 2009; 583(3):579–584. doi:10.1016/j.febslet.2008.12.064. [PubMed: 19162022]
179. Watt AD, Villemagne VL, Barnham KJ. Metals, membranes, and amyloid-beta oligomers: key pieces in the Alzheimer's disease puzzle? *J Alzheimer Dis*. 2013; 33(Suppl 1):S283–S293. doi: 10.3233/jad-2012-129017.
180. Wilcox KC, Marunde MR, Das A, Velasco PT, Kuhns B, Marty MT, Jiang H, Luan C-H, Sligar SG, Klein WL. Nanoscale synaptic membrane mimetic allows unbiased high throughput screen that targets binding sites for Alzheimer's-associated A β oligomers. *PloS One*. 2015 In Press.
181. Wilhelmus MM, de Jager M, Bakker EN, Drukarch B. Tissue transglutaminase in Alzheimer's disease: involvement in pathogenesis and its potential as a therapeutic target. *J Alzheimer Dis*. 2014; 42:S289–S303. doi:10.3233/jad-132492.
182. Wisniewski T, Goni F. Immunotherapy for Alzheimer's disease. *Biochem Pharmacol*. 2014; 88(4):499–507. doi:10.1016/j.bcp.2013.12.020. [PubMed: 24412277]
183. Xiao C, Davis FJ, Chauhan BC, Viola KL, Lacor PN, Velasco PT, Klein WL, Chauhan NB. Brain transit and ameliorative effects of intranasally delivered anti-amyloid-beta oligomer antibody in 5XFAD mice. *J Alzheimer Dis*. 2013; 35(4):777–788. doi:10.3233/jad-122419.
184. Xu S, Liu G, Bao X, Wu J, Li S, Zheng B, Anwyl R, Wang Q. Rosiglitazone prevents amyloid-beta oligomer-induced impairment of synapse formation and plasticity via increasing dendrite and spine mitochondrial number. *J Alzheimer Dis*. 2014; 39(2):239–251. doi:10.3233/jad-130680.
185. Yang F, Lim GP, Begum AN, Ubeda OJ, Simmons MR, Ambegaokar SS, Chen PP, Kayed R, Glabe CG, Frautschy SA, Cole GM. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. *J Biol Chem*. 2005; 280(7):5892–5901. doi: 10.1074/jbc.M404751200. [PubMed: 15590663]
186. Yates EA, Owens SL, Lynch MF, Cucco EM, Umbaugh CS, Legleiter J. Specific domains of Abeta facilitate aggregation on and association with lipid bilayers. *J Mol Biol*. 2013; 425(11): 1915–1933. doi:10.1016/j.jmb.2013.03.022. [PubMed: 23524134]
187. Younan ND, Sarell CJ, Davies P, Brown DR, Viles JH. The cellular prion protein traps Alzheimer's Abeta in an oligomeric form and disassembles amyloid fibers. *FASEB J Off Publ Fed Am Soc Exp Biol*. 2013; 27(5):1847–1858. doi:10.1096/fj.12-222588.
188. Yuan Z, Du M, Chen Y, Dou F. Construction of human Fab library and screening of a single-domain antibody of amyloid-beta 42 oligomers. *Neural Regener Res*. 2013; 8(33):3107–3115. doi:10.3969/j.issn.1673-5374.2013.33.004.
189. Zahs KR, Ashe KH. beta-Amyloid oligomers in aging and Alzheimer's disease. *Front Aging Neurosci*. 2013; 5:28. doi:10.3389/fnagi.2013.00028. [PubMed: 23847532]
190. Zempel H, Mandelkow E. Lost after translation: missorting of Tau protein and consequences for Alzheimer disease. *Trend Neurosci*. 2014 doi:10.1016/j.tins.2014.08.004.
191. Zempel H, Thies E, Mandelkow E, Mandelkow EM. Abeta oligomers cause localized Ca(2+) elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines. *J Neurosci*. 2010; 30(36):11938–11950. doi:10.1523/jneurosci.2357-10.2010. [PubMed: 20826658]

192. Zhang J, Peng M, Jia J. Plasma Amyloid-beta Oligomers and Soluble Tumor Necrosis Factor Receptors as Potential Bio-markers of AD. *Current Alzheimer research*. 2014
193. Zhang L, Yagnik G, Peng Y, Wang J, Xu HH, Hao Y, Liu YN, Zhou F. Kinetic studies of inhibition of the amyloid beta (1-42) aggregation using a ferrocene-tagged beta-sheet breaker peptide. *Anal Biochem*. 2013; 434(2):292–299. doi:10.1016/j.ab.2012.11.025. [PubMed: 23232068]
194. Zhao M, Wang SW, Wang YJ, Zhang R, Li YN, Su YJ, Zhou WW, Yu XL, Liu RT. Pan-amyloid oligomer specific scFv antibody attenuates memory deficits and brain amyloid burden in mice with Alzheimer's disease. *Curr Alzheimer Res*. 2014; 11(1):69–78. [PubMed: 24156260]
195. Zhao WQ, De Felice FG, Fernandez S, Chen H, Lambert MP, Quon MJ, Krafft GA, Klein WL. Amyloid beta oligomers induce impairment of neuronal insulin receptors. *FASEB J Off Publ Fed Am Soc Exp Biol*. 2008; 22(1):246–260. doi:10.1096/fj.06-7703com.
196. Zheng L, Calvo-Garrido J, Hallbeck M, Hultenby K, Marcusson J, Cedazo-Minguez A, Terman A. Intracellular localization of amyloid-beta peptide in SH-SY5Y neuroblastoma cells. *J Alzheimer's Dis*. 2013; 37(4):713–733. doi:10.3233/jad-122455. [PubMed: 23948913]

Fig. 1. Aβ oligomers (AβOs) instigate neuron damage in Alzheimer’s disease. **a** Oligomeric Aβ, rather than insoluble amyloid species, instigates neuron damage in AD (adapted from the “2004/2005 Progress Report on Alzheimer’s disease” Health and Human Services). **b** AD-associated changes attributed to AβOs

Fig. 2. Perisomatic AβOs consistent with synapse binding are present early in human neuropathology. *Left* Low magnification of human cortical brain section stained with an anti-oligomer antibody. Scattered individual neurons are surrounded by AβOs in early AD, before the appearance of amyloid plaques. The perineuronal distribution of these AβOs (*right*) is consistent with a binding site within the dendritic arbor. *Scale bar* 10 μm. Adapted from Lacor et al. [91]

Fig. 3.

Dysfunctional insulin signaling induced by A β Os provides one link to AD etiology. Diabetes causes a reduction in brain insulin and brain insulin signaling as well as an increase in glucose and lipids. This leads to an increase in A β production and a reduction in A β O clearance, causing a buildup of oligomers in the brain. As A β O levels rise, they bind synapses and cause neuronal damage, resulting in a decrease in insulin receptors and further reducing insulin signaling in brain cells. This vicious cycle results in cognitive failure and AD.

Fig. 4.

AβOs can accumulate in intracellular and extracellular pools. Intracellular AβOs are detectable in animal models overproducing APP and Aβ; however, the presence of extracellular AβOs on dendrites and in CSF suggests they are also important in AD. *Left* A representative micrograph of confocal fluorescence labeling of amyloid-β peptide (Aβ)-oligomer-specific antibody NU1 immunoreaction in young, pre-plaque Tg mice shows intracellular localization of AβOs. Adapted from Ferretti et al. [40]. *Right* A scatter plot from the ultrasensitive scanometric detection of AβOs in cerebrospinal fluid. Adapted from Georganopoulou et al. [45]. The response for the negative human control subject (brain extract) was similar to that observed for the chip control. The data points are averages of several separate experiments normalized for each assay based on the highest response in a series of runs. The mean values for ADDL concentrations (*solid lines*) are estimated for each group based on a calibration curve

Fig. 5.

Synthetic and brain-derived A β Os are ligands that target synapses. A β Os extracted from AD brain or prepared in vitro show punctate binding to neuronal cell surface proteins. Cultured hippocampal neurons were incubated with synthetic A β Os or soluble extracts of human brain. Binding was visualized by immunofluorescence microscopy by using a polyclonal anti-A β oligomer antibody, M93. Synthetic A β Os (*Left*), soluble extracts of non-AD control brains (*Center*), and soluble AD-brain extracts (*Right*) are shown. Small puncta, bound largely along neurites, are evident for AD extracts and synthetic A β Os but not for control extracts. *Bar* 10 μ m. Adapted from Gong et al. [47]

Fig. 6.

Model for Aβ oligomer-induced synaptic dysfunction involving PrPc and Fyn. Extracellular Aβ monomer, produced through cleavage of the amyloid precursor protein (APP) by both β- and γ-secretase, assembles into toxic Aβ oligomers. These AβOs bind to cellular prion protein (PrP^C) and activate Fyn tyrosine kinase, possibly through a yet to be identified transmembrane protein. AβO activation of Fyn signaling drives the tyrosine phosphorylation of NMDA receptors, which in turn produces altered surface expression, dysregulation of receptor function, excitotoxicity and dendritic spine retraction. Adapted from Um and Strittmatter [170]

Fig. 7.

A surfeit of toxin receptor candidates. Provided is a current list of candidate A β /A β oligomer receptors that have been proposed over the last 20 years. No single candidate has been shown to be necessary and sufficient to account for all aspects of A β O binding and toxicity

Fig. 8.

Single molecule trafficking shows AβOs stop diffusion of mGluR5 and “hijack” membrane proteins that can lead to elevated Ca^{2+} . *Left panels* Dual-color single-particle tracking was used to monitor mGluR5 (red) and biotin-AβO (green) diffusion at synapses over time. Following the tracings of mGluR5, mGluR5 diffuses together with an AβO (5 min) outside synapses before both become stabilized at a synaptic site (60 min). Adapted from Renner et al. [143]. *Right* Clustering of membrane proteins, possibly involving PrPc, leads to AβO binding recruitment and membrane receptor reorganization that instigates toxic signaling. AβO binding to an unidentified receptor, X, and the recruitment of effector protein co-receptors leads to hyperactive Ca^{2+} signaling and downstream toxicity

Fig. 9.

AβOs cause pathological tau redistribution. AβOs (ADDLs) induce missorting of Tau and neurofilaments into the somatodendritic compartment of primary hippocampal neurons that suggests a mechanism for AD nerve cell death. *Left, top* There is no colocalization of Tau and MAP2 in vehicle-treated control cells. Tau is predominantly localized to the axonal compartment (antibody K9JA—green), while MAP2 is localized to the somatodendritic compartment (antibody AP20—red). *Left, bottom* In ADDL-treated cells (5 μM for 3 h), Tau is redistributed into soma and dendrites (green), where it colocalizes with MAP2 (red). *Arrows* indicate colocalization of MAP2 and Tau. Adapted from Zempel et al. [191]. *Right* Data suggest a mechanism for AD neuronal cell death that involves AβO-induced breakdown of Tau sorting and neuronal polarity. Aβ induces missorting of Tau, which in turn leads to a loss of microtubules, impaired trafficking (e.g., of mitochondria), and loss of spines, ultimately leading to neuronal death. Adapted from Zempel and Mandelkow [190]

Fig. 10.

Diverse structural outcomes from different aggregation protocols. AFM images revealing a spectrum of A β structures are shown. **a** Fibrils: A β_{1-42} aged in ddH₂O for one week contains periodic and smooth fibrils throughout the field of diverse sizes and lengths. **b** Rings: A β_{1-42} aged in F12 at 37 °C for 24 h and not centrifuged contains many ring-like structures and a few short linear protofibrils. **c** A β Os/protofibrils: A β_{1-42} aged in PBS for 48 h at RT contains many linear protofibrillar structures and small, spherical structures. Protofibrillar structures appear to contain bead-by-bead assemblies of multiple globular structures. The results suggest that temperature and chemical environment are critical during A β aggregation. *Scale bar* 400 nm. From Chromy et al. [16]

Fig. 11.

Capture of receptors for A β oligomers in nanodiscs and a high-throughput assay to screen for unknown therapeutic targets. *Top* Schematic of Nanodisc formation using synaptic plasma membranes. Each Nanodisc consists of a discoidal lipid bilayer stabilized by artificial membrane scaffold proteins (MSP) with His tags. A small fraction of the population contains A β O-binding proteins. His tags on Nanodiscs and biotin on A β O provide a means for conducting binding assays. *Bottom* Aurin tricarboxylic acid (ATA) potentially reduces synaptic A β O accumulation in culture. ATA was assayed at 1 μ M for a preventative effect on A β O accumulation at synapses in cultured rat hippocampal neurons. Images shown are of typical neurons after treatment with A β O (*left panel*) or A β O following ATA pre-treatment (*right panel*). A β O are shown in *green*, neurons identified by β 3 tubulin fluorescence are *white*, and DAPI is *blue* to indicate nuclei. Selected neurites are enlarged below each image to illustrate the distribution of bound A β O. Scale bar 10 μ m. Adapted from Wilcox et al. [180]

Fig. 12.

Diagnostic assays for A β oligomer levels provide A β O-relevant MRI signals in brain. **a** Sagittal brain sections, 50 μ m thick, from 8-month-old 5xFAD and wt mice were probed with 568-NU4 and counterstained with Thioflavin S. Image shows a 5xFAD cortical region stained with both NU4 (red) and thioflavin S (green). NU4 labeling is more abundant than the ThioS staining. Findings demonstrate that NU4 labeling is often associated with, yet distinct from, amyloid plaques. Scale 25 μ m. **b** In vivo imaging of NU4MNS distribution in live mice 4 h after intranasal inoculation shows labeling by the probe in the hippocampal region of the Tg mice, but not the wt controls. Scale bar 5 mm. **c** Higher magnification of the hippocampal region of the Tg and wt mice shows probe distribution 4 h after inoculation, the changes in distribution 96 h later, and the distribution of the target after re-administering the probe on Day 5. Data suggest that non oligomer-associated probe is clearing the brain. Scale bar 1 mm. Adapted from Viola et al. [174]